المؤلفون: Abduraimova A. B, Usmanov S. M, Nazarova D

المصدر: Journal of Universal Science Research, 2(6), 62-69, (2024-06-05)

مصطلحات موضوعية: Лазерное сканирование, контрольные точки, Тахеометр, Autodesk Recap

Relation: https://doi.org/10.5281/zenodo.11489664; https://doi.org/10.5281/zenodo.11489665; oai:zenodo.org:11489665

الاتاحة: https://doi.org/10.5281/zenodo.11489665

المؤلفون: Anastasia Sergeevna Belevich, M. I. Yarmolinskaya, Sergey Alekseevich Selkov, Dmitriy Igorevich Sokolov, Анастасия Сергеевна Белевич, М. И. Ярмолинская, Сергей Алексеевич Сельков, Дмитрий Игоревич Соколов

المساهمون: Работы выполнена в рамках ФНИ № 122041500063-2

المصدر: Medical Immunology (Russia); Online First ; Медицинская иммунология; Online First ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-0-0

مصطلحات موضوعية: контрольные точки, эндометриоз, CTLA-4, PD-1, LAG-3, Tim-3, TIGIT, 4-1BB, GITR

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2923/1920; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13088; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13089; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13090; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13091; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13092; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13093; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13094; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13134; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13135; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13155; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13156; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2923/13546; Abramiuk M., Bebnowska D., Hrynkiewicz R., Polak P.N.G., Kotarski J., Rolinski J.,Grywalska E. CLTA-4 Expression is Associated with the Maintenance of Chronic Inflammation in Endometriosis and Infertility. Cells, 2021, Vol.10, no 3. [10.3390/cells10030487] https://www.ncbi.nlm.nih.gov/pubmed/33668701; Abramiuk M., Frankowska K., Kulak K., Tarkowski R., Mertowska P., Mertowski S.,Grywalska E. Possible Correlation between Urocortin 1 (Ucn1) and Immune Parameters in Patients with Endometriosis. Int J Mol Sci, 2023, Vol.24, no 9. [10.3390/ijms24097787] https://www.ncbi.nlm.nih.gov/pubmed/37175494; Agic A., Djalali S., Wolfler M.M., Halis G., Diedrich K.,Hornung D. Combination of CCR1 mRNA, MCP1, and CA125 measurements in peripheral blood as a diagnostic test for endometriosis. Reprod Sci, 2008, Vol.15, no 9, pp. 906-11. [10.1177/1933719108318598] https://www.ncbi.nlm.nih.gov/pubmed/19050323; Akhtar K., Sravanthi M.V., D'Angelo J.,Sivapiragasam A. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios. J Investig Med High Impact Case Rep, 2022, Vol.10, no, pp. 23247096221121408. [10.1177/23247096221121408] https://www.ncbi.nlm.nih.gov/pubmed/36017984; Akinboro O., Larkins E., Pai-Scherf L.H., Mathieu L.N., Ren Y., Cheng J., Fiero M.H., Fu W., Bi Y., Kalavar S., Jafri S., Mishra-Kalyani P.S., Fourie Zirkelbach J., Li H., Zhao H., He K., Helms W.S., Chuk M.K., Wang M., Bulatao I., Herz J., Osborn B.L., Xu Y., Liu J., Gong Y., Sickafuse S., Cohen R., Donoghue M., Pazdur R., Beaver J.A.,Singh H. FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC. Clin Cancer Res, 2022, Vol.28, no 11, pp. 2221-2228. [10.1158/1078-0432.CCR-21-3844] https://www.ncbi.nlm.nih.gov/pubmed/35101885; Alsharedi M., Srivastava R.,Elmsherghi N. Durvalumab for the treatment of urothelial carcinoma. Drugs Today (Barc), 2017, Vol.53, no 12, pp. 647-652. [10.1358/dot.2017.53.12.2733054] https://www.ncbi.nlm.nih.gov/pubmed/29517083; Anglesio M.S., Papadopoulos N., Ayhan A., Nazeran T.M., Noe M., Horlings H.M., Lum A., Jones S., Senz J., Seckin T., Ho J., Wu R.C., Lac V., Ogawa H., Tessier-Cloutier B., Alhassan R., Wang A., Wang Y., Cohen J.D., Wong F., Hasanovic A., Orr N., Zhang M., Popoli M., McMahon W., Wood L.D., Mattox A., Allaire C., Segars J., Williams C., Tomasetti C., Boyd N., Kinzler K.W., Gilks C.B., Diaz L., Wang T.L., Vogelstein B., Yong P.J., Huntsman D.G.,Shih I.M. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med, 2017, Vol.376, no 19, pp. 1835-1848. [10.1056/NEJMoa1614814] https://www.ncbi.nlm.nih.gov/pubmed/28489996; Arabpour M., Ghods A., Shariat M., Talei A.R., Mehdipour F.,Ghaderi A. Correlation of 4-1BBL+ B Cells in Tumor Draining Lymph Nodes with Pathological Characteristics of Breast Cancer. Iran J Immunol, 2019, Vol.16, no 2, pp. 108-116. [10.22034/IJI.2019.80254] https://www.ncbi.nlm.nih.gov/pubmed/31182685; Atkinson V., Khattak A., Haydon A., Eastgate M., Roy A., Prithviraj P., Mueller C., Brignone C.,Triebel F. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. J Immunother Cancer, 2020, Vol.8, no 2. [10.1136/jitc-2020-001681] https://www.ncbi.nlm.nih.gov/pubmed/33219094; Azimnasab-Sorkhabi P., Soltani-Asl M.,Kfoury Junior J.R. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells. Hum Cell, 2023, Vol.36, no 4, pp. 1225-1232. [10.1007/s13577-023-00893-8] https://www.ncbi.nlm.nih.gov/pubmed/36907978; Baptista M.Z., Sarian L.O., Derchain S.F., Pinto G.A.,Vassallo J. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol, 2016, Vol.47, no 1, pp. 78-84. [10.1016/j.humpath.2015.09.006] https://www.ncbi.nlm.nih.gov/pubmed/26541326; Bardhan K., Anagnostou T.,Boussiotis V.A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol, 2016, Vol.7, no, pp. 550. [10.3389/fimmu.2016.00550] https://www.ncbi.nlm.nih.gov/pubmed/28018338; Barra F., Ferro Desideri L., Leone Roberti Maggiore U., Gaetano Vellone V., Maramai M., Scala C.,Ferrero S. Endometriosis Classification and The Role of Tumor Necrosis Factor-Alpha Polymorphisms as A Therapeutic Target. Int J Fertil Steril, 2020, Vol.14, no 1, pp. 76-77. [10.22074/ijfs.2020.5876] https://www.ncbi.nlm.nih.gov/pubmed/32112641; Bartkowiak T.,Curran M.A. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol, 2015, Vol.5, no, pp. 117. [10.3389/fonc.2015.00117] https://www.ncbi.nlm.nih.gov/pubmed/26106583; Bettini M., Szymczak-Workman A.L., Forbes K., Castellaw A.H., Selby M., Pan X., Drake C.G., Korman A.J.,Vignali D.A. Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol, 2011, Vol.187, no 7, pp. 3493-8. [10.4049/jimmunol.1100714] https://www.ncbi.nlm.nih.gov/pubmed/21873518; Borrelli G.M., Abrao M.S.,Mechsner S. Can chemokines be used as biomarkers for endometriosis? A systematic review. Hum Reprod, 2014, Vol.29, no 2, pp. 253-66. [10.1093/humrep/det401] https://www.ncbi.nlm.nih.gov/pubmed/24287816; Brinton L.A., Gridley G., Persson I., Baron J.,Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol, 1997, Vol.176, no 3, pp. 572-9. [10.1016/s0002-9378(97)70550-7] https://www.ncbi.nlm.nih.gov/pubmed/9077609; Brinton L.A., Sakoda L.C., Sherman M.E., Frederiksen K., Kjaer S.K., Graubard B.I., Olsen J.H.,Mellemkjaer L. Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev, 2005, Vol.14, no 12, pp. 2929-35. [10.1158/1055-9965.EPI-05-0394] https://www.ncbi.nlm.nih.gov/pubmed/16365012; Brubel R., Bokor A., Pohl A., Schilli G.K., Szereday L., Bacher-Szamuel R., Rigo J., Jr.,Polgar B. Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. Fertil Steril, 2017, Vol.108, no 6, pp. 1016-1025 e2. [10.1016/j.fertnstert.2017.09.008] https://www.ncbi.nlm.nih.gov/pubmed/29202955; Burghaus S., Drazic P., Wolfler M., Mechsner S., Zeppernick M., Meinhold-Heerlein I., Mueller M.D., Rothmund R., Vigano P., Becker C.M., Zondervan K.T., Beckmann M.W., Fasching P.A., Berner-Gatz S., Grunewald F.S., Hund M., Kastner P., Klammer M., Laubender R.P., Wegmeyer H., Wienhues-Thelen U.H.,Renner S.P. Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study. Int J Gynaecol Obstet, 2023 no. [10.1002/ijgo.15062] https://www.ncbi.nlm.nih.gov/pubmed/37635683; Cakir Y., Talu C.K., Trabulus D.C.,Mermut O. The immunohistochemical Galectin-3 expression in tumor and cancer-associated fibroblasts in invasive ductal carcinomas of breast and their relationship with clinicopathological parameters. Indian J Pathol Microbiol, 2023, Vol.66, no 3, pp. 456-464. [10.4103/ijpm.ijpm_284_21] https://www.ncbi.nlm.nih.gov/pubmed/37530324; Canales Rojas R. Update on immunotherapy for renal cancer. Medwave, 2021, Vol.21, no 5, pp. e8202. [10.5867/medwave.2021.05.8202] https://www.ncbi.nlm.nih.gov/pubmed/34214067; Cao Y., Zhou X., Huang X., Li Q., Gao L., Jiang L., Huang M.,Zhou J. Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS One, 2013, Vol.8, no 1, pp. e53834. [10.1371/journal.pone.0053834] https://www.ncbi.nlm.nih.gov/pubmed/23335978; Caserta D., Di Benedetto L., Bordi G., D'Ambrosio A.,Moscarini M. Levels of Galectin-3 and Stimulation Expressed Gene 2 in the peritoneal fluid of women with endometriosis: a pilot study. Gynecol Endocrinol, 2014, Vol.30, no 12, pp. 877-80. [10.3109/09513590.2014.943728] https://www.ncbi.nlm.nih.gov/pubmed/25069762; Chambers C.A., Kuhns M.S., Egen J.G.,Allison J.P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol, 2001, Vol.19, no, pp. 565-94. [10.1146/annurev.immunol.19.1.565] https://www.ncbi.nlm.nih.gov/pubmed/11244047; Chattopadhyay S.,Chakraborty N.G. GITR expression on T-cell receptor-stimulated human CD8 T cell in a JNK-dependent pathway. Indian J Hum Genet, 2009, Vol.15, no 3, pp. 121-4. [10.4103/0971-6866.60188] https://www.ncbi.nlm.nih.gov/pubmed/21088717; Chen S., Liu Y., Zhong Z., Wei C., Liu Y.,Zhu X. Peritoneal immune microenvironment of endometriosis: Role and therapeutic perspectives. Front Immunol, 2023, Vol.14, no, pp. 1134663. [10.3389/fimmu.2023.1134663] https://www.ncbi.nlm.nih.gov/pubmed/36865552; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971222/pdf/fimmu-14-1134663.pdf; Chen T., Wei J.L., Leng T., Gao F.,Hou S.Y. The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis. J Clin Lab Anal, 2021, Vol.35, no 9, pp. e23947. [10.1002/jcla.23947] https://www.ncbi.nlm.nih.gov/pubmed/34405450; Chen W.C., Cheng C.M., Liao W.T.,Chang T.C. Urinary Biomarkers for Detection of Clinical Endometriosis or Adenomyosis. Biomedicines, 2022, Vol.10, no 4. [10.3390/biomedicines10040833] https://www.ncbi.nlm.nih.gov/pubmed/35453583; https://mdpi-res.com/d_attachment/biomedicines/biomedicines-10-00833/article_deploy/biomedicines-10-00833.pdf?version=1648819036; Chen X., Du Y., Hu Q.,Huang Z. Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4. Pathol Res Pract, 2017, Vol.213, no 3, pp. 245-249. [10.1016/j.prp.2016.12.008] https://www.ncbi.nlm.nih.gov/pubmed/28214198; Chen Z., Huang J., Kwak-Kim J.,Wang W. Immune checkpoint inhibitors and reproductive failures. J Reprod Immunol, 2023, Vol.156, no, pp. 103799. [10.1016/j.jri.2023.103799] https://www.ncbi.nlm.nih.gov/pubmed/36724630; Cheng L.S., Cheng Y.F., Liu W.T., Shen A., Zhang D., Xu T., Yin W., Cheng M., Ma X., Wang F., Zhao Q., Zeng X., Zhang Y.,Shen G. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. J Transl Med, 2022, Vol.20, no 1, pp. 415. [10.1186/s12967-022-03619-w] https://www.ncbi.nlm.nih.gov/pubmed/36076251; Chester C., Ambulkar S.,Kohrt H.E. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother, 2016, Vol.65, no 10, pp. 1243-8. [10.1007/s00262-016-1829-2] https://www.ncbi.nlm.nih.gov/pubmed/27034234; Chester C., Sanmamed M.F., Wang J.,Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood, 2018, Vol.131, no 1, pp. 49-57. [10.1182/blood-2017-06-741041] https://www.ncbi.nlm.nih.gov/pubmed/29118009; Choi Y.S., Kim S., Oh Y.S., Cho S.,Hoon Kim S. Elevated serum interleukin-32 levels in patients with endometriosis: A cross-sectional study. Am J Reprod Immunol, 2019, Vol.82, no 2, pp. e13149. [10.1111/aji.13149] https://www.ncbi.nlm.nih.gov/pubmed/31099938; Claus C., Ferrara-Koller C.,Klein C. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. MAbs, 2023, Vol.15, no 1, pp. 2167189. [10.1080/19420862.2023.2167189] https://www.ncbi.nlm.nih.gov/pubmed/36727218; Collins J.M.,Gulley J.L. Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother, 2019, Vol.15, no 4, pp. 891-908. [10.1080/21645515.2018.1551671] https://www.ncbi.nlm.nih.gov/pubmed/30481100; Contardi E., Palmisano G.L., Tazzari P.L., Martelli A.M., Fala F., Fabbi M., Kato T., Lucarelli E., Donati D., Polito L., Bolognesi A., Ricci F., Salvi S., Gargaglione V., Mantero S., Alberghini M., Ferrara G.B.,Pistillo M.P. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer, 2005, Vol.117, no 4, pp. 538-50. [10.1002/ijc.21155] https://www.ncbi.nlm.nih.gov/pubmed/15912538; Daud A.I., Wolchok J.D., Robert C., Hwu W.J., Weber J.S., Ribas A., Hodi F.S., Joshua A.M., Kefford R., Hersey P., Joseph R., Gangadhar T.C., Dronca R., Patnaik A., Zarour H., Roach C., Toland G., Lunceford J.K., Li X.N., Emancipator K., Dolled-Filhart M., Kang S.P., Ebbinghaus S.,Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol, 2016, Vol.34, no 34, pp. 4102-4109. [10.1200/JCO.2016.67.2477] https://www.ncbi.nlm.nih.gov/pubmed/27863197; De Mello R.A.B., Voscaboinik R., Luciano J.V.P., Cremonese R.V., Amaral G.A., Castelo-Branco P.,Antoniou G. Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. Cancers (Basel), 2021, Vol.14, no 1. [10.3390/cancers14010122] https://www.ncbi.nlm.nih.gov/pubmed/35008287; Duan X., Liu J., Cui J., Ma B., Zhou Q., Yang X., Lu Z., Du Y.,Su C. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. Mol Med Rep, 2019, Vol.20, no 4, pp. 3773-3781. [10.3892/mmr.2019.10641] https://www.ncbi.nlm.nih.gov/pubmed/31485637; Dumic J., Dabelic S.,Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta, 2006, Vol.1760, no 4, pp. 616-35. [10.1016/j.bbagen.2005.12.020] https://www.ncbi.nlm.nih.gov/pubmed/16478649; Eggermont A.M.,Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer, 2011, Vol.47, no 14, pp. 2150-7. [10.1016/j.ejca.2011.06.052] https://www.ncbi.nlm.nih.gov/pubmed/21802280; Eurich K., De La Cruz P., Laguna A., Woodman M., McAdams J., Lips E., Ebott J., DiSilvestro J., Ribeiro J.,James N. Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer. Gynecol Oncol, 2023, Vol.174, no, pp. 200-207. [10.1016/j.ygyno.2023.05.015] https://www.ncbi.nlm.nih.gov/pubmed/37224792; Finkelmeier F., Waidmann O.,Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther, 2018, Vol.18, no 12, pp. 1169-1175. [10.1080/14737140.2018.1535315] https://www.ncbi.nlm.nih.gov/pubmed/30304963; Geng H., Zhang G.M., Xiao H., Yuan Y., Li D., Zhang H., Qiu H., He Y.F.,Feng Z.H. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int J Cancer, 2006, Vol.118, no 11, pp. 2657-64. [10.1002/ijc.21795] https://www.ncbi.nlm.nih.gov/pubmed/16425224; Gu Q., Li J., Chen Z., Zhang J., Shen H., Miao X., Zhou Y., Xu X.,He S. Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma. Front Oncol, 2021, Vol.11, no, pp. 664032. [10.3389/fonc.2021.664032] https://www.ncbi.nlm.nih.gov/pubmed/34178648; Guney G., Taskin M.I., Lagana A.S., Tolu E., Aslan F., Hismiogullari A.A.,Kaya C. Neutrophil gelatinase-associated lipocalin serum level: A potential noninvasive biomarker of endometriosis? Medicine (Baltimore), 2023, Vol.102, no 41, pp. e35539. [10.1097/MD.0000000000035539] https://www.ncbi.nlm.nih.gov/pubmed/37832065; Guo B., Chen J.H., Zhang J.H., Fang Y., Liu X.J., Zhang J., Zhu H.Q.,Zhan L. Pattern-recognition receptors in endometriosis: A narrative review. Front Immunol, 2023, Vol.14, no, pp. 1161606. [10.3389/fimmu.2023.1161606] https://www.ncbi.nlm.nih.gov/pubmed/37033937; Gurney A.L., Marsters S.A., Huang R.M., Pitti R.M., Mark D.T., Baldwin D.T., Gray A.M., Dowd A.D., Brush A.D., Heldens A.D., Schow A.D., Goddard A.D., Wood W.I., Baker K.P., Godowski P.J.,Ashkenazi A. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol, 1999, Vol.9, no 4, pp. 215-8. [10.1016/s0960-9822(99)80093-1] https://www.ncbi.nlm.nih.gov/pubmed/10074428; Hafler D.A.,Kuchroo V. TIMs: central regulators of immune responses. J Exp Med, 2008, Vol.205, no 12, pp. 2699-701. [10.1084/jem.20082429] https://www.ncbi.nlm.nih.gov/pubmed/19015312; Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., Honjo T.,Fujii S. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A, 2007, Vol.104, no 9, pp. 3360-5. [10.1073/pnas.0611533104] https://www.ncbi.nlm.nih.gov/pubmed/17360651; He Y., Jia K., Dziadziuszko R., Zhao S., Zhang X., Deng J., Wang H., Hirsch F.R.,Zhou C. Galectin-9 in non-small cell lung cancer. Lung Cancer, 2019, Vol.136, no, pp. 80-85. [10.1016/j.lungcan.2019.08.014] https://www.ncbi.nlm.nih.gov/pubmed/31454748; He Y., Rivard C.J., Rozeboom L., Yu H., Ellison K., Kowalewski A., Zhou C.,Hirsch F.R. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci, 2016, Vol.107, no 9, pp. 1193-7. [10.1111/cas.12986] https://www.ncbi.nlm.nih.gov/pubmed/27297395; Hemon P., Jean-Louis F., Ramgolam K., Brignone C., Viguier M., Bachelez H., Triebel F., Charron D., Aoudjit F., Al-Daccak R.,Michel L. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol, 2011, Vol.186, no 9, pp. 5173-83. [10.4049/jimmunol.1002050] https://www.ncbi.nlm.nih.gov/pubmed/21441454; Henry L., Vervier J., Boucher A., Brichant G., Gaspard O., Labied S., Munaut C., Ravet S.,Nisolle M. Oocyte Cryopreservation in Patients with Endometriosis: Current Knowledge and Number Needed to Treat. J Clin Med, 2022, Vol.11, no 15. [10.3390/jcm11154559] https://www.ncbi.nlm.nih.gov/pubmed/35956174; Hong J.H., Cho H.W., Ouh Y.T., Lee J.K.,Chun Y. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer. J Gynecol Oncol, 2023, Vol.34, no 2, pp. e18. [10.3802/jgo.2023.34.e18] https://www.ncbi.nlm.nih.gov/pubmed/36509464; Huang R.Y., Francois A., McGray A.R., Miliotto A.,Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology, 2017, Vol.6, no 1, pp. e1249561. [10.1080/2162402X.2016.1249561] https://www.ncbi.nlm.nih.gov/pubmed/28197366; Huo J.L., Wang Y.T., Fu W.J., Lu N.,Liu Z.S. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol, 2022, Vol.13, no, pp. 956090. [10.3389/fimmu.2022.956090] https://www.ncbi.nlm.nih.gov/pubmed/35958563; Incognito G.G., Di Guardo F., Gulino F.A., Genovese F., Benvenuto D., Lello C.,Palumbo M. Interleukin-6 as A Useful Predictor of Endometriosis-Associated Infertility: A Systematic Review. Int J Fertil Steril, 2023, Vol.17, no 4, pp. 226-230. [10.22074/ijfs.2023.557683.1329] https://www.ncbi.nlm.nih.gov/pubmed/37577903; Jansa V., Pusic Novak M., Ban Frangez H.,Rizner T.L. TGFBI as a candidate biomarker for non-invasive diagnosis of early-stage endometriosis. Hum Reprod, 2023, Vol.38, no 7, pp. 1284-1296. [10.1093/humrep/dead091] https://www.ncbi.nlm.nih.gov/pubmed/37187159; Jarollahi S., Chaichian S., Jarollahi A., Hajmohammadi R., Mashayekhi R., Shahmohammadi F., Eslamivaghar M.,Ghasemi Z. The Diagnostic Accuracy of Galectin-9 for Diagnosis of Endometriosis in Comparison with Laparoscopy. J Reprod Infertil, 2022, Vol.23, no 4, pp. 271-278. [10.18502/jri.v23i4.10812] https://www.ncbi.nlm.nih.gov/pubmed/36452187; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674464/pdf/JRI-23-271.pdf; Jeung I., Cheon K.,Kim M.R. Decreased Cytotoxicity of Peripheral and Peritoneal Natural Killer Cell in Endometriosis. Biomed Res Int, 2016, Vol.2016, no, pp. 2916070. [10.1155/2016/2916070] https://www.ncbi.nlm.nih.gov/pubmed/27294113; Jiang J., Jiang Z.,Xue M. Serum and peritoneal fluid levels of interleukin-6 and interleukin-37 as biomarkers for endometriosis. Gynecol Endocrinol, 2019, Vol.35, no 7, pp. 571-575. [10.1080/09513590.2018.1554034] https://www.ncbi.nlm.nih.gov/pubmed/30632819; Jolicoeur C., Boutouil M., Drouin R., Paradis I., Lemay A.,Akoum A. Increased expression of monocyte chemotactic protein-1 in the endometrium of women with endometriosis. Am J Pathol, 1998, Vol.152, no 1, pp. 125-33. https://www.ncbi.nlm.nih.gov/pubmed/9422530; Kang C. Retifanlimab: First Approval. Drugs, 2023, Vol.83, no 8, pp. 731-737. [10.1007/s40265-023-01884-7] https://www.ncbi.nlm.nih.gov/pubmed/37184754; Kang Y.J., Jeung I.C., Park A., Park Y.J., Jung H., Kim T.D., Lee H.G., Choi I.,Yoon S.R. An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression. Hum Reprod, 2014, Vol.29, no 10, pp. 2176-89. [10.1093/humrep/deu172] http://www.ncbi.nlm.nih.gov/pubmed/25035432; Kaya C., Alay I., Guraslan H., Gedikbasi A., Ekin M., Ertas Kaya S., Oral E.,Yasar L. The Role of Serum Caspase 3 Levels in Prediction of Endometriosis Severity. Gynecol Obstet Invest, 2018, Vol.83, no 6, pp. 576-585. [10.1159/000489494] https://www.ncbi.nlm.nih.gov/pubmed/30071521; Keir M.E., Butte M.J., Freeman G.J.,Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008, Vol.26, no, pp. 677-704. [10.1146/annurev.immunol.26.021607.090331] https://www.ncbi.nlm.nih.gov/pubmed/18173375; Kimber-Trojnar Z., Pilszyk A., Niebrzydowska M., Pilszyk Z., Ruszala M.,Leszczynska-Gorzelak B. The Potential of Non-Invasive Biomarkers for Early Diagnosis of Asymptomatic Patients with Endometriosis. J Clin Med, 2021, Vol.10, no 13. [10.3390/jcm10132762] https://www.ncbi.nlm.nih.gov/pubmed/34201813; Kong F., Jin M., Cao D., Jia Z., Liu Y.,Jiang J. Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma. PeerJ, 2020, Vol.8, no, pp. e9949. [10.7717/peerj.9949] https://www.ncbi.nlm.nih.gov/pubmed/32995093; Kovalak E.E., Karacan T., Zengi O., Karabay Akgul O., Ozyurek S.E.,Guraslan H. Evaluation of new biomarkers in stage III and IV endometriosis. Gynecol Endocrinol, 2023, Vol.39, no 1, pp. 2217290. [10.1080/09513590.2023.2217290] https://www.ncbi.nlm.nih.gov/pubmed/37236244; Krummel M.F.,Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med, 1995, Vol.182, no 2, pp. 459-65. [10.1084/jem.182.2.459] https://www.ncbi.nlm.nih.gov/pubmed/7543139; Laudanski P., Rogalska G., Warzecha D., Lipa M., Manka G., Kiecka M., Spaczynski R., Piekarski P., Banaszewska B., Jakimiuk A., Issat T., Rokita W., Mlodawski J., Szubert M., Sieroszewski P., Raba G., Szczupak K., Kluz T., Kluza M., Neuman T., Adler P., Peterson H., Salumets A.,Wielgos M. Autoantibody screening of plasma and peritoneal fluid of patients with endometriosis. Hum Reprod, 2023, Vol.38, no 4, pp. 629-643. [10.1093/humrep/dead011] https://www.ncbi.nlm.nih.gov/pubmed/36749097; Lee M.Y., Kim S.H., Oh Y.S., Heo S.H., Kim K.H., Chae H.D., Kim C.H.,Kang B.M. Role of interleukin-32 in the pathogenesis of endometriosis: in vitro, human and transgenic mouse data. Hum Reprod, 2018, Vol.33, no 5, pp. 807-816. [10.1093/humrep/dey055] https://www.ncbi.nlm.nih.gov/pubmed/29562285; Li C., Zhou J., Shao J., Yuan L., Cheng Q., Wang L.,Duan Z. Decrease in CD226 expression on CD4(+) T cells in patients with endometriosis. Biosci Trends, 2023, Vol.17, no 2, pp. 168-171. [10.5582/bst.2022.01501] https://www.ncbi.nlm.nih.gov/pubmed/37081668; Li J., Yan S., Li Q., Huang Y., Ji M., Jiao X., Yuan M.,Wang G. Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis. Mol Hum Reprod, 2022, Vol.28, no 5. [10.1093/molehr/gaac010] https://www.ncbi.nlm.nih.gov/pubmed/35404426; Li Y., Zhang J., Zhang D., Hong X., Tao Y., Wang S., Xu Y., Piao H., Yin W., Yu M., Zhang Y., Fu Q., Li D., Chang X.,Du M. Tim-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates pregnancy loss. Sci Signal, 2017, Vol.10, no 498. [10.1126/scisignal.aah4323] https://www.ncbi.nlm.nih.gov/pubmed/28951537; Liu Q., Ma P., Liu L., Ma G., Ma J., Liu X., Liu Y., Lin W.,Zhu Y. Evaluation of PLGA containing anti-CTLA4 inhibited endometriosis progression by regulating CD4+CD25+Treg cells in peritoneal fluid of mouse endometriosis model. Eur J Pharm Sci, 2017, Vol.96, no, pp. 542-550. [10.1016/j.ejps.2016.10.031] https://www.ncbi.nlm.nih.gov/pubmed/27989857; Lozano E., Dominguez-Villar M., Kuchroo V.,Hafler D.A. The TIGIT/CD226 axis regulates human T cell function. J Immunol, 2012, Vol.188, no 8, pp. 3869-75. [10.4049/jimmunol.1103627] https://www.ncbi.nlm.nih.gov/pubmed/22427644; Mahnke K.,Enk A.H. TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention. J Invest Dermatol, 2016, Vol.136, no 1, pp. 9-11. [10.1016/j.jid.2015.10.048] https://www.ncbi.nlm.nih.gov/pubmed/26763417; Man Y., Dai C., Guo Q., Jiang L.,Shi Y. A novel PD-1/PD-L1 pathway molecular typing-related signature for predicting prognosis and the tumor microenvironment in breast cancer. Discov Oncol, 2023, Vol.14, no 1, pp. 59. [10.1007/s12672-023-00669-4] https://www.ncbi.nlm.nih.gov/pubmed/37154982; Martin-Liberal J., Kordbacheh T.,Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf, 2015, Vol.14, no 6, pp. 957-64. [10.1517/14740338.2015.1021774] https://www.ncbi.nlm.nih.gov/pubmed/25927979; Martire F.G., Russo C., Selntigia A., Nocita E., Soreca G., Lazzeri L., Zupi E.,Exacoustos C. Early noninvasive diagnosis of endometriosis: dysmenorrhea and specific ultrasound findings are important indicators in young women. Fertil Steril, 2023, Vol.119, no 3, pp. 455-464. [10.1016/j.fertnstert.2022.12.004] https://www.ncbi.nlm.nih.gov/pubmed/36493871; Maruhashi T., Sugiura D., Okazaki I.M.,Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer, 2020, Vol.8, no 2. [10.1136/jitc-2020-001014] https://www.ncbi.nlm.nih.gov/pubmed/32929051; Matalliotakis I., Neonaki M., Zolindaki A., Hassan E., Georgoulias V.,Koumantakis E. Changes in immunologic variables (TNF-a, sCD8 and sCD4) during danazol treatment in patients with endometriosis. Int J Fertil Womens Med, 1997, Vol.42, no 3, pp. 211-4. https://www.ncbi.nlm.nih.gov/pubmed/9222806; Matsubara E., Shinchi Y., Komohara Y., Yano H., Pan C., Fujiwara Y., Ikeda K.,Suzuki M. PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma. Med Mol Morphol, 2023 no. [10.1007/s00795-023-00361-0] https://www.ncbi.nlm.nih.gov/pubmed/37402054; Meggyes M., Szereday L., Bohonyi N., Koppan M., Szegedi S., Marics-Kutas A., Marton M., Totsimon A.,Polgar B. Different Expression Pattern of TIM-3 and Galectin-9 Molecules by Peripheral and Peritoneal Lymphocytes in Women with and without Endometriosis. Int J Mol Sci, 2020, Vol.21, no 7. [10.3390/ijms21072343] https://www.ncbi.nlm.nih.gov/pubmed/32231038; https://mdpi-res.com/d_attachment/ijms/ijms-21-02343/article_deploy/ijms-21-02343-v2.pdf?version=1585549834; Mikus M., Goldstajn M.S., Brlecic I., Dumancic S., Lagana A.S., Chiantera V., Vujic G.,Coric M. CTLA4-Linked Autoimmunity in the Pathogenesis of Endometriosis and Related Infertility: A Systematic Review. Int J Mol Sci, 2022, Vol.23, no 18. [10.3390/ijms231810902] https://www.ncbi.nlm.nih.gov/pubmed/36142815; Motamedi M., Shahbaz S., Fu L., Dunsmore G., Xu L., Harrington R., Houston S.,Elahi S. Galectin-9 Expression Defines a Subpopulation of NK Cells with Impaired Cytotoxic Effector Molecules but Enhanced IFN-gamma Production, Dichotomous to TIGIT, in HIV-1 Infection. Immunohorizons, 2019, Vol.3, no 11, pp. 531-546. [10.4049/immunohorizons.1900087] https://www.ncbi.nlm.nih.gov/pubmed/31732662; Muharam R., Bustami A., Gusti Mansur I., Zulkifli Jacoeb T., Giustiniani J., Schiavon V.,Bensussan A. Cytotoxic activity of peripheral blood mononuclear cells in patients with endometriosis: A cross-sectional study. Int J Reprod Biomed, 2022, Vol.20, no 8, pp. 691-700. [10.18502/ijrm.v20i8.11758] https://www.ncbi.nlm.nih.gov/pubmed/36313261; Murakami D., Matsuda K., Iwamoto H., Mitani Y., Mizumoto Y., Nakamura Y., Matsuzaki I., Iwamoto R., Takahashi Y., Kojima F., Murata S.I.,Yamaue H. Prognostic value of CD155/TIGIT expression in patients with colorectal cancer. PLoS One, 2022, Vol.17, no 3, pp. e0265908. [10.1371/journal.pone.0265908] https://www.ncbi.nlm.nih.gov/pubmed/35324958; Mutti L., Valle M.T., Balbi B., Orengo A.M., Lazzaro A., Alciato P., Gatti E., Betta P.G.,Pozzi E. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Int J Cancer, 1998, Vol.78, no 6, pp. 740-9. [10.1002/(sici)1097-0215(19981209)78:63.0.co;2-5] https://www.ncbi.nlm.nih.gov/pubmed/9833768; Naseri S., Rosenberg-Hasson Y., Maecker H.T., Avrutsky M.I.,Blumenthal P.D. A cross-sectional study comparing the inflammatory profile of menstrual effluent vs. peripheral blood. Health Sci Rep, 2023, Vol.6, no 1, pp. e1038. [10.1002/hsr2.1038] https://www.ncbi.nlm.nih.gov/pubmed/36620506; Nasr S., Haddad F.G., Khazen J., Kattan J.,Trak-Smayra V. PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience. BMC Cancer, 2023, Vol.23, no 1, pp. 817. [10.1186/s12885-023-11299-y] https://www.ncbi.nlm.nih.gov/pubmed/37658290; Neumann M., Murphy N.,Seetharamu N. The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab. Cancer Med J, 2022, Vol.5, no 1, pp. 31-45. https://www.ncbi.nlm.nih.gov/pubmed/35253011; Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., Nakamura S., Enomoto K., Yagita H., Azuma M.,Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res, 2007, Vol.13, no 7, pp. 2151-7. [10.1158/1078-0432.CCR-06-2746] https://www.ncbi.nlm.nih.gov/pubmed/17404099; Oksasoglu B., Hepokur C., Misir S., Yildiz C., Sonmez G.,Yanik A. Determination of PD-1 expression in peripheral blood cells in patients with endometriosis. Gynecol Endocrinol, 2021, Vol.37, no 2, pp. 157-161. [10.1080/09513590.2020.1821358] https://www.ncbi.nlm.nih.gov/pubmed/33078970; Olkowska-Truchanowicz J., Bialoszewska A., Zwierzchowska A., Sztokfisz-Ignasiak A., Janiuk I., Dabrowski F., Korczak-Kowalska G., Barcz E., Bocian K.,Malejczyk J. Peritoneal Fluid from Patients with Ovarian Endometriosis Displays Immunosuppressive Potential and Stimulates Th2 Response. Int J Mol Sci, 2021, Vol.22, no 15. [10.3390/ijms22158134] https://www.ncbi.nlm.nih.gov/pubmed/34360900; Ortiz C.N., Torres-Reveron A.,Appleyard C.B. Metabolomics in endometriosis: challenges and perspectives for future studies. Reprod Fertil, 2021, Vol.2, no 2, pp. R35-R50. [10.1530/RAF-20-0047] https://www.ncbi.nlm.nih.gov/pubmed/35128453; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812441/pdf/RAF-20-0047.pdf; Othman Eel D., Hornung D., Salem H.T., Khalifa E.A., El-Metwally T.H.,Al-Hendy A. Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. Eur J Obstet Gynecol Reprod Biol, 2008, Vol.137, no 2, pp. 240-6. [10.1016/j.ejogrb.2007.05.001] https://www.ncbi.nlm.nih.gov/pubmed/17582674; Othman E.R., Hornung D., Hussein M., Abdelaal, II, Sayed A.A., Fetih A.N.,Al-Hendy A. Soluble tumor necrosis factor-alpha receptors in the serum of endometriosis patients. Eur J Obstet Gynecol Reprod Biol, 2016, Vol.200, no, pp. 1-5. [10.1016/j.ejogrb.2016.02.025] https://www.ncbi.nlm.nih.gov/pubmed/26963895; Oyama R., Kanayama M., Mori M., Matsumiya H., Taira A., Shinohara S., Takenaka M., Yoneda K., Kuroda K.,Tanaka F. CD155 expression and its clinical significance in non-small cell lung cancer. Oncol Lett, 2022, Vol.23, no 5, pp. 166. [10.3892/ol.2022.13286] https://www.ncbi.nlm.nih.gov/pubmed/35414831; Pan H.Y.,Wan J. Serum HSF1 is upregulated in endometriosis patients and serves as a potential diagnostic biomarker. Kaohsiung J Med Sci, 2023, Vol.39, no 10, pp. 1045-1051. [10.1002/kjm2.12723] https://www.ncbi.nlm.nih.gov/pubmed/37409787; Popovici R.M., Krause M.S., Germeyer A., Strowitzki T.,von Wolff M. Galectin-9: a new endometrial epithelial marker for the mid- and late-secretory and decidual phases in humans. J Clin Endocrinol Metab, 2005, Vol.90, no 11, pp. 6170-6. [10.1210/jc.2004-2529] https://www.ncbi.nlm.nih.gov/pubmed/16105962; Qi H., Li Y., Liu X., Jiang Y., Li Z., Xu X., Zhang H.,Hu X. Tim-3 regulates the immunosuppressive function of decidual MDSCs via the Fyn-STAT3-C/EBPbeta pathway during Toxoplasma gondii infection. PLoS Pathog, 2023, Vol.19, no 4, pp. e1011329. [10.1371/journal.ppat.1011329] https://www.ncbi.nlm.nih.gov/pubmed/37058540; Raschi E., Comito F., Massari F.,Gelsomino F. Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. Immunotherapy, 2023, Vol.15, no 2, pp. 85-91. [10.2217/imt-2022-0172] https://www.ncbi.nlm.nih.gov/pubmed/36628573; Rondon L., Fu R.,Patel M.R. Success of Checkpoint Blockade Paves the Way for Novel Immune Therapy in Malignant Pleural Mesothelioma. Cancers (Basel), 2023, Vol.15, no 11. [10.3390/cancers15112940] https://www.ncbi.nlm.nih.gov/pubmed/37296902; Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res, 2019, Vol.38, no 1, pp. 255. [10.1186/s13046-019-1259-z] https://www.ncbi.nlm.nih.gov/pubmed/31196207; Sansone A.M., Hisrich B.V., Young R.B., Abel W.F., Bowens Z., Blair B.B., Funkhouser A.T., Schammel D.P., Green L.J., Lessey B.A.,Blenda A.V. Evaluation of BCL6 and SIRT1 as Non-Invasive Diagnostic Markers of Endometriosis. Curr Issues Mol Biol, 2021, Vol.43, no 3, pp. 1350-1360. [10.3390/cimb43030096] https://www.ncbi.nlm.nih.gov/pubmed/34698105; Santoso B., Sa'adi A., Dwiningsih S.R., Tunjungseto A., Widyanugraha M.Y.A., Mufid A.F., Rahmawati N.Y.,Ahsan F. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility. Am J Reprod Immunol, 2020, Vol.84, no 4, pp. e13296. [10.1111/aji.13296] https://www.ncbi.nlm.nih.gov/pubmed/32593225; Shafrir A.L., Farland L.V., Shah D.K., Harris H.R., Kvaskoff M., Zondervan K.,Missmer S.A. Risk for and consequences of endometriosis: A critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol, 2018, Vol.51, no, pp. 1-15. [10.1016/j.bpobgyn.2018.06.001] https://www.ncbi.nlm.nih.gov/pubmed/30017581; Shah M., Osgood C.L., Amatya A.K., Fiero M.H., Pierce W.F., Nair A., Herz J., Robertson K.J., Mixter B.D., Tang S., Pazdur R., Beaver J.A.,Amiri-Kordestani L. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res, 2022, Vol.28, no 24, pp. 5249-5253. [10.1158/1078-0432.CCR-22-1110] https://www.ncbi.nlm.nih.gov/pubmed/35925043; Shigesi N., Kvaskoff M., Kirtley S., Feng Q., Fang H., Knight J.C., Missmer S.A., Rahmioglu N., Zondervan K.T.,Becker C.M. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum Reprod Update, 2019, Vol.25, no 4, pp. 486-503. [10.1093/humupd/dmz014] https://www.ncbi.nlm.nih.gov/pubmed/31260048; Simone R., Pesce G., Antola P., Rumbullaku M., Bagnasco M., Bizzaro N.,Saverino D. The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses. Biomed Res Int, 2014, Vol.2014, no, pp. 215763. [10.1155/2014/215763] https://www.ncbi.nlm.nih.gov/pubmed/24605322; Souza D.S., Macheroni C., Pereira G.J.S., Vicente C.M.,Porto C.S. Molecular regulation of prostate cancer by Galectin-3 and estrogen receptor. Front Endocrinol (Lausanne), 2023, Vol.14, no, pp. 1124111. [10.3389/fendo.2023.1124111] https://www.ncbi.nlm.nih.gov/pubmed/36936148; Stanietsky N., Simic H., Arapovic J., Toporik A., Levy O., Novik A., Levine Z., Beiman M., Dassa L., Achdout H., Stern-Ginossar N., Tsukerman P., Jonjic S.,Mandelboim O. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A, 2009, Vol.106, no 42, pp. 17858-63. [10.1073/pnas.0903474106] https://www.ncbi.nlm.nih.gov/pubmed/19815499; Stasenko M., Smith E., Yeku O., Park K.J., Laster I., Lee K., Walderich S., Spriggs E., Rueda B., Weigelt B., Zamarin D., Rao T.D.,Spriggs D.R. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. Sci Rep, 2021, Vol.11, no 1, pp. 3718. [10.1038/s41598-021-82686-3] https://www.ncbi.nlm.nih.gov/pubmed/33580170; Suszczyk D., Skiba W., Zardzewialy W., Pawlowska A., Wlodarczyk K., Polak G., Tarkowski R.,Wertel I. Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis. Int J Mol Sci, 2022, Vol.23, no 19. [10.3390/ijms231911607] https://www.ncbi.nlm.nih.gov/pubmed/36232911; https://mdpi-res.com/d_attachment/ijms/ijms-23-11607/article_deploy/ijms-23-11607-v2.pdf?version=1665309498; Suzman D.L., Agrawal S., Ning Y.M., Maher V.E., Fernandes L.L., Karuri S., Tang S., Sridhara R., Schroeder J., Goldberg K.B., Ibrahim A., McKee A.E., Pazdur R.,Beaver J.A. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. Oncologist, 2019, Vol.24, no 4, pp. 563-569. [10.1634/theoncologist.2018-0084] https://www.ncbi.nlm.nih.gov/pubmed/30541754; Sznol M. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J, 2014, Vol.20, no 4, pp. 290-5. [10.1097/PPO.0000000000000056] https://www.ncbi.nlm.nih.gov/pubmed/25098290; Tahermanesh K., Hakimpour S., Govahi A., Rokhgireh S., Mehdizadeh M., Minaeian S., Barati M., Chaichian S., Kashi A.M., Nassiri S., Eslahi N., Ajdary M.,Ahmadi M. Evaluation of expression of biomarkers of PLAGL1 (ZAC1), microRNA, and their non-coding RNAs in patients with endometriosis. J Gynecol Obstet Hum Reprod, 2023, Vol.52, no 4, pp. 102568. [10.1016/j.jogoh.2023.102568] https://www.ncbi.nlm.nih.gov/pubmed/36868502; Tanaka E., Sendo F., Kawagoe S.,Hiroi M. Decreased natural killer cell activity in women with endometriosis. Gynecol Obstet Invest, 1992, Vol.34, no 1, pp. 27-30. [10.1159/000292720] https://www.ncbi.nlm.nih.gov/pubmed/1526528; Tang T., Lai H., Huang X., Gu L.,Shi H. Application of serum markers in diagnosis and staging of ovarian endometriosis. J Obstet Gynaecol Res, 2021, Vol.47, no 4, pp. 1441-1450. [10.1111/jog.14654] https://www.ncbi.nlm.nih.gov/pubmed/33448139; Tella S.H., Kommalapati A., Mahipal A.,Jin Z. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Biomedicines, 2022, Vol.10, no 6. [10.3390/biomedicines10061304] https://www.ncbi.nlm.nih.gov/pubmed/35740326; Timmerman J., Herbaux C., Ribrag V., Zelenetz A.D., Houot R., Neelapu S.S., Logan T., Lossos I.S., Urba W., Salles G., Ramchandren R., Jacobson C., Godwin J., Carpio C., Lathers D., Liu Y., Neely J., Suryawanshi S., Koguchi Y.,Levy R. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol, 2020, Vol.95, no 5, pp. 510-520. [10.1002/ajh.25757] https://www.ncbi.nlm.nih.gov/pubmed/32052473; Vellanki P.J., Mulkey F., Jaigirdar A.A., Rodriguez L., Wang Y., Xu Y., Zhao H., Liu J., Howe G., Wang J., Choo Q., Golding S.J., Mansell V., Korsah K., Spillman D., de Claro R.A., Pazdur R., Beaver J.A.,Singh H. FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review. Clin Cancer Res, 2021, Vol.27, no 13, pp. 3522-3527. [10.1158/1078-0432.CCR-20-4338] https://www.ncbi.nlm.nih.gov/pubmed/33632925; Vence L., Bucktrout S.L., Fernandez Curbelo I., Blando J., Smith B.M., Mahne A.E., Lin J.C., Park T., Pascua E., Sai T., Chaparro-Riggers J., Subudhi S.K., Scutti J.B., Higa M.G., Zhao H., Yadav S.S., Maitra A., Wistuba, II, Allison J.P.,Sharma P. Characterization and Comparison of GITR Expression in Solid Tumors. Clin Cancer Res, 2019, Vol.25, no 21, pp. 6501-6510. [10.1158/1078-0432.CCR-19-0289] https://www.ncbi.nlm.nih.gov/pubmed/31358539; Villanacci R., Bandini V., Ottolina J., Pagliardini L., Candiani M.,Vigano P. The pathogenesis of endometriosis: clues from the immunological evidence. Minerva Obstet Gynecol, 2021, Vol.73, no 3, pp. 275-282. [10.23736/S2724-606X.21.04768-7] https://www.ncbi.nlm.nih.gov/pubmed/34008382; Vinay D.S.,Kwon B.S. 4-1BB signaling beyond T cells. Cell Mol Immunol, 2011, Vol.8, no 4, pp. 281-4. [10.1038/cmi.2010.82] http://www.ncbi.nlm.nih.gov/pubmed/21217771; http://www.nature.com/cmi/journal/v8/n4/pdf/cmi201082a.pdf; von Euw E., Chodon T., Attar N., Jalil J., Koya R.C., Comin-Anduix B.,Ribas A. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med, 2009, Vol.7, no, pp. 35. [10.1186/1479-5876-7-35] https://www.ncbi.nlm.nih.gov/pubmed/19457253; Walankiewicz M., Grywalska E., Polak G., Korona-Glowniak I., Witt E., Surdacka A., Kotarski J.,Rolinski J. The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters. Mediators Inflamm, 2018, Vol.2018, no, pp. 7041342. [10.1155/2018/7041342] https://www.ncbi.nlm.nih.gov/pubmed/30595667; Wang X.B., Fan Z.Z., Anton D., Vollenhoven A.V., Ni Z.H., Chen X.F.,Lefvert A.K. CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation. BMC Immunol, 2011, Vol.12, no, pp. 21. [10.1186/1471-2172-12-21] https://www.ncbi.nlm.nih.gov/pubmed/21414236; Wang Y., Du J., Gao Z., Sun H., Mei M., Wang Y., Ren Y.,Zhou X. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer, 2023, Vol.128, no 7, pp. 1196-1207. [10.1038/s41416-022-02084-y] https://www.ncbi.nlm.nih.gov/pubmed/36522474; Wang Y., Feng T., Li H., Xiong Y.,Tao Y. Gal-9/Tim-3 signaling pathway activation suppresses the generation of Th17 cells and promotes the induction of Foxp3(+) regulatory T cells in renal ischemia-reperfusion injury. Mol Immunol, 2023, Vol.156, no, pp. 136-147. [10.1016/j.molimm.2023.03.008] https://www.ncbi.nlm.nih.gov/pubmed/36921488; Warzecha D., Zalecka J., Manka G., Kiecka M., Lipa M., Spaczynski R., Piekarski P., Banaszewska B., Jakimiuk A., Issat T., Rokita W., Mlodawski J., Szubert M., Sieroszewski P., Raba G., Szczupak K., Kluz T., Kluza M., Wielgos M., Oldak L., Lesniewska A., Gorodkiewicz E.,Laudanski P. Plasma and Peritoneal Fluid Fibronectin and Collagen IV Levels as Potential Biomarkers of Endometriosis. Int J Mol Sci, 2022, Vol.23, no 24. [10.3390/ijms232415669] https://www.ncbi.nlm.nih.gov/pubmed/36555313; Wessels J.M., Kay V.R., Leyland N.A., Agarwal S.K.,Foster W.G. Assessing brain-derived neurotrophic factor as a novel clinical marker of endometriosis. Fertil Steril, 2016, Vol.105, no 1, pp. 119-28 e1-5. [10.1016/j.fertnstert.2015.09.003] https://www.ncbi.nlm.nih.gov/pubmed/26409150; Wiles K.N., Tsikretsis L.E., Alioto C.M., Hermida de Viveiros P.A., Villaflor V.M.,Tetreault M.P. GITR agonistic stimulation enhances the anti-tumor immune response in a mouse model of ESCC. Carcinogenesis, 2022, Vol.43, no 9, pp. 908-918. [10.1093/carcin/bgac064] https://www.ncbi.nlm.nih.gov/pubmed/35880612; Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., Nomura T.,Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008, Vol.322, no 5899, pp. 271-5. [10.1126/science.1160062] http://www.ncbi.nlm.nih.gov/pubmed/18845758; Wroblewski J.M., Bixby D.L., Borowski C.,Yannelli J.R. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer, 2001, Vol.33, no 2-3, pp. 181-94. [10.1016/s0169-5002(01)00210-0] https://www.ncbi.nlm.nih.gov/pubmed/11551413; Wu L., Lv C., Su Y., Li C., Zhang H., Zhao X.,Li M. Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. Gynecol Endocrinol, 2019, Vol.35, no 3, pp. 251-256. [10.1080/09513590.2018.1519787] https://www.ncbi.nlm.nih.gov/pubmed/30325236; Xu F., Liu J., Liu D., Liu B., Wang M., Hu Z., Du X., Tang L.,He F. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res, 2014, Vol.74, no 13, pp. 3418-28. [10.1158/0008-5472.CAN-13-2690] https://www.ncbi.nlm.nih.gov/pubmed/24769443; Xu J.X., Maher V.E., Zhang L., Tang S., Sridhara R., Ibrahim A., Kim G.,Pazdur R. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. Oncologist, 2017, Vol.22, no 3, pp. 311-317. [10.1634/theoncologist.2016-0476] https://www.ncbi.nlm.nih.gov/pubmed/28232599; Xue C., Zhu D., Chen L., Xu Y., Xu B., Zhang D.,Jiang J. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer. Transl Cancer Res, 2019, Vol.8, no 1, pp. 111-119. [10.21037/tcr.2019.01.09] https://www.ncbi.nlm.nih.gov/pubmed/35116740; Yamashita S., Hashimoto K., Sawada I., Ogawa M., Nakatsuka E., Kawano M., Kinose Y., Kodama M., Sawada K.,Kimura T. Endometrial galectin-3 causes endometriosis by supporting eutopic endometrial cell survival and engraftment in the peritoneal cavity. Am J Reprod Immunol, 2022, Vol.87, no 6, pp. e13533. [10.1111/aji.13533] https://www.ncbi.nlm.nih.gov/pubmed/35366371; Yan J., Zhang Y., Zhang J.P., Liang J., Li L.,Zheng L. Tim-3 expression defines regulatory T cells in human tumors. PLoS One, 2013, Vol.8, no 3, pp. e58006. [10.1371/journal.pone.0058006] https://www.ncbi.nlm.nih.gov/pubmed/23526963; Yang M., Yu Q., Liu J., Fu W., Cao Y., Yu L., Shao S., Wang X., Niu H.,Wang Y. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. J Surg Oncol, 2015, Vol.112, no 4, pp. 430-5. [10.1002/jso.24012] https://www.ncbi.nlm.nih.gov/pubmed/26265374; Yasinska I.M., Sakhnevych S.S., Pavlova L., Teo Hansen Selno A., Teuscher Abeleira A.M., Benlaouer O., Goncalves Silva I., Mosimann M., Varani L., Bardelli M., Hussain R., Siligardi G., Cholewa D., Berger S.M., Gibbs B.F., Ushkaryov Y.A., Fasler-Kan E., Klenova E.,Sumbayev V.V. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. Front Immunol, 2019, Vol.10, no, pp. 1594. [10.3389/fimmu.2019.01594] https://www.ncbi.nlm.nih.gov/pubmed/31354733; Yildiz C., Caner A., Oksasoglu B., Misir S., Yaylim I.,Hepokur C. The role of cytokeratin 19 levels in the determination of endometriosis stages. Gynecol Endocrinol, 2022, Vol.38, no 10, pp. 879-884. [10.1080/09513590.2022.2120606] https://www.ncbi.nlm.nih.gov/pubmed/36068968; Zhang C., Xu L., Ma Y., Huang Y., Zhou L., Le H.,Chen Z. Increased TIM-3 expression in tumor-associated macrophages predicts a poorer prognosis in non-small cell lung cancer: a retrospective cohort study. J Thorac Dis, 2023, Vol.15, no 3, pp. 1433-1444. [10.21037/jtd-23-227] https://www.ncbi.nlm.nih.gov/pubmed/37065598; Zhang Y., Wu L., Wen X.,Lv X. Identification and validation of risk score model based on gene set activity as a diagnostic biomarker for endometriosis. Heliyon, 2023, Vol.9, no 7, pp. e18277. [10.1016/j.heliyon.2023.e18277] https://www.ncbi.nlm.nih.gov/pubmed/37539146; Zhang Y., Yang R., Xu C., Zhang Y., Deng M., Wu D., Tang F., Liu X., Han Y., Zhan Y.,Miao J. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy. Pathol Res Pract, 2022, Vol.236, no, pp. 153990. [10.1016/j.prp.2022.153990] https://www.ncbi.nlm.nih.gov/pubmed/35749914; Zhang Y., Yao Q., Pan Y., Fang X., Xu H., Zhao T., Zhu G., Jiang T., Li S.,Cao H. Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review. Cancers (Basel), 2023, Vol.15, no 3. [10.3390/cancers15030682] https://www.ncbi.nlm.nih.gov/pubmed/36765640; Zhang Y., Zhang H., Wei M., Mou T., Shi T., Ma Y., Cai X., Li Y., Dong J.,Wei J. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8(+) T Cells in HCC. Mol Ther, 2019, Vol.27, no 11, pp. 1906-1918. [10.1016/j.ymthe.2019.07.019] https://www.ncbi.nlm.nih.gov/pubmed/31466933; Zhang Y.,Zheng J. Functions of Immune Checkpoint Molecules Beyond Immune Evasion. Adv Exp Med Biol, 2020, Vol.1248, no, pp. 201-226. [10.1007/978-981-15-3266-5_9] https://www.ncbi.nlm.nih.gov/pubmed/32185712; Zheng D., Hou X., Yu J.,He X. Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. Front Pharmacol, 2022, Vol.13, no, pp. 928369. [10.3389/fphar.2022.928369] https://www.ncbi.nlm.nih.gov/pubmed/35935874; Zheng L., Sun D.F.,Tong Y. Exosomal miR-202 derived from leukorrhea as a potential biomarker for endometriosis. J Int Med Res, 2023, Vol.51, no 1, pp. 3000605221147183. [10.1177/03000605221147183] https://www.ncbi.nlm.nih.gov/pubmed/36597409; Zhou E., Huang Q., Wang J., Fang C., Yang L., Zhu M., Chen J., Chen L.,Dong M. Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer. Int J Clin Exp Pathol, 2015, Vol.8, no 7, pp. 8018-27. https://www.ncbi.nlm.nih.gov/pubmed/26339368; Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B.,Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol, 2005, Vol.6, no 12, pp. 1245-52. [10.1038/ni1271] https://www.ncbi.nlm.nih.gov/pubmed/16286920; Zhu H., Wang M., Du Y., Liu X., Weng X.,Li C. 4-1BBL has a Possible Role in Mediating Castration-Resistant Conversion of Prostate Cancer via Up-Regulation of Androgen Receptor. J Cancer, 2019, Vol.10, no 11, pp. 2464-2471. [10.7150/jca.29648] https://www.ncbi.nlm.nih.gov/pubmed/31258752; Ziogas I.A., Evangeliou A.P., Giannis D., Hayat M.H., Mylonas K.S., Tohme S., Geller D.A., Elias N., Goyal L.,Tsoulfas G. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist, 2021, Vol.26, no 6, pp. e1036-e1049. [10.1002/onco.13638] https://www.ncbi.nlm.nih.gov/pubmed/33314549; https://www.mimmun.ru/mimmun/article/view/2923

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2923
https://doi.org/10.15789/1563-0625-CIT-2923

المؤلفون: Александр Иванович Яшкин

المصدر: Ползуновский вестник, Vol 1, Iss 4, Pp 133-139 (2022)

مصطلحات موضوعية: полукопченые колбасы, оленина, мясо марала, качество продукции, безопасность продукции, технология, система хассп, критические контрольные точки, корректирующие действия., Technology

وصف الملف: electronic resource

Relation: https://ojs.altstu.ru/index.php/PolzVest/article/view/281; https://doaj.org/toc/2072-8921

URL الوصول: https://doaj.org/article/c38a6c5b89eb45ec87373b4e54d90373

المؤلفون: А.В. Четверяков, В.Л. Цепелев

المصدر: Российские биомедицинские исследования, Vol 8, Iss 2 (2023)

مصطلحات موضوعية: колоректальный рак, LAG-3, иммунитет, иммунные контрольные точки, Medicine (General), R5-920

وصف الملف: electronic resource

Relation: http://ojs3.gpmu.org/index.php/biomedical-research/article/view/5617; https://doaj.org/toc/2658-6584; https://doaj.org/toc/2658-6576

URL الوصول: https://doaj.org/article/c43b3ec5f9c84452a5f4f91217b0b172

المؤلفون: ЛЕОНТЬЕВ АЛЕКСАНДР САВЕЛЬЕВИЧ, ТИМОШКИН МАКСИМ СЕРГЕЕВИЧ

المصدر: Наукосфера, 4(2),2023, (2023-04-24)

مصطلحات موضوعية: вычислительный комплекс, многоуровневые модели, контрольные точки, уравнение, структурная избыточность, функции распределения, преобразование Лапласа-Стильтьеса

Relation: https://doi.org/10.5281/zenodo.7860605; https://doi.org/10.5281/zenodo.7860606; oai:zenodo.org:7860606

الاتاحة: https://doi.org/10.5281/zenodo.7860606

المؤلفون: A. Yu. Kuzevanova, O. A. Khalmurzaev, A. A. Borunova, N. V. Apanovich, T. N. Zabotina, A. A. Alimov, V. B. Matveev, A. V. Karpukhin, А. Ю. Кузеванова, О. А. Халмурзаев, А. А. Борунова, Н. В. Апанович, Т. Н. Заботина, А. А. Алимов, В. Б. Матвеев, А. В. Карпухин

المساهمون: The research was carried out within the state assignment of Ministry of Science and Higher Education of the Russian Federation for Research Centre for Medical Genetics., Исследование выполнено в рамках государственного задания Минобрнауки России для ФГБНУ «Медико-генетический научный центр им. акад. Н.П. Бочкова»

المصدر: Cancer Urology; Том 18, № 4 (2022); 15-24 ; Онкоурология; Том 18, № 4 (2022); 15-24 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: иммунные контрольные точки, T-cell, renal cell carcinoma, model, immune checkpoints, Т-клетки, почечно-клеточный рак, модель

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1634/1412; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1634/1214; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.; Мерабишвили В.М., Полторацкий А.Н., Носов А.К. и др. Состояние онкологической помощи в России. Рак почки (заболеваемость, смертность, достоверность учета, одногодичная и погодичная летальность, гистологическая структура). Часть 1. Онкоурология 2021;17(2):182–94. DOI:10.17650/1726-97762021-17-2-182-194; Носов Д.А., Алексеев Б.Я., Гладков О.А. и др. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли: Практические рекомендации RUSSCO 2021;11(3s2):31. DOI:10.18027/2224-5057-2021-11-3s2-31; Alva A., Daniels G.A., Wong M.K. et. al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother 2016;65(12):1533–44. DOI:10.1007/s00262-016-1910-x; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116–27. DOI:10.1056/NEJMoa1816714; Chevrier S., Levine J.H., Zanotelli V.R.T. et al. An immune atlas of clear cell renal cell carcinoma. Cell 2017;169(4):736–49.e18. DOI:10.1016/j.cell.2017.04.016; Xu Y., Miller C.P., Warren E.H., Tykodi S.S. Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. Hum Vaccin Immunother 2021;17(7):1882–96. DOI:10.1080/21645515.2020.1870846; Raimondi A., Sepe P., Zattarin E. et al. Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer. Front Oncol 2020;10:1644. DOI:10.3389/fonc.2020.01644; Shen M., Chen G., Xie Q. et al. Association between PD-L1 expression and the prognosis and clinicopathologic features of renal cell carcinoma: a systematic review and meta-analysis. Urol Int 2020;104(7–8):533–41. DOI:10.1159/000506296; Набережнов Д.С., Морозов А.А., Фридман М.В. и др. Система PD-1/PD-L1 при иммунотерапии рака почки. Часть 2. Маркеры и препараты иммунотерапии рака почки. Медицинский алфавит 2019;1(10):54–61. DOI:10.33667/2078-5631-2019-1-10(385)-54-61; Braun D.A., Hou Y., Bakouny Z. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med 2020;26(6):909–18. DOI:10.1038/s41591-020-0839-y; Борунова А.А., Заботина Т.Н., Шоуа Э.К. и др. Cубпопуляционная структура лимфоцитов периферической крови доноров. Российский биотерапевтический журнал 2020;19(4):54–64. DOI:10.17650/1726-9784-2020-19-4-54-64; Jang Y.Y., Cho D., Kim S.K. et al. An improved flow cytometrybased natural killer cytotoxicity assay involving calcein AM staining of effector cells. Ann Clin Lab Sci 2012;42(1):42–9.; Coronnello C., Busà R., Cicero L. et. al. Radioactive-free method for the thorough analysis of the kinetics of cell cytotoxicity. J Imaging 2021;7(11):222. DOI:10.3390/jimaging7110222; https://oncourology.abvpress.ru/oncur/article/view/1634

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1634
https://doi.org/10.17650/1726-9776-2022-18-4-15-24

المؤلفون: N. V. Apanovich, P. V. Apanovich, O. A. Khalmurzaev, V. B. Matveev, A. A. Alimov, Н. В. Апанович, П. В. Апанович, О. А. Халмурзаев, В. Б. Матвеев, А. А. Алимов

المساهمون: Работа выполнена по государственному заданию Минобрнауки России для ФГБНУ «Медико-генетический научный центр имени академика Н.П. Бочкова».

المصدر: Medical Genetics; Том 22, № 11 (2023); 13-19 ; Медицинская генетика; Том 22, № 11 (2023); 13-19 ; 2073-7998

مصطلحات موضوعية: метастазы, expression, renal cancer, immune checkpoint, metastasis, экспрессия, рак почки, иммунные контрольные точки

وصف الملف: application/pdf

Relation: https://www.medgen-journal.ru/jour/article/view/2369/1748; Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA A Cancer J. Clin. 2023; 73: 17–48.; Ljungberg B., Albiges L., Bedke J., et al. EAU Guidelines on Renal Cell Carcinoma; 2023; ISBN 978-94-92671-19-6.; Мерабишвили В.М., Полторацкий А.Н., Носов А.К., и др. Состояние онкологической помощи в России. Рак почки (заболеваемость, смертность, достоверность учета, одногодичная и погодичная летальность, гистологическая структура). Часть 1. Онкоурология. 2021; 17(2): 182-194. DOI:10.17650/1726-97762021-17-2-182-194; Athanazio D.A., Amorim L.S., da Cunha I.W., et al. Classification of renal cell tumors – current concepts and use of ancillary tests: recommendations of the Brazilian Society of Pathology. Surg Exp Pathol 4, 4. 2021. https://doi.org/10.1186/s42047-020-00084-x.; Makino T., Kadomoto S., Izumi K., Mizokami A. Epidemiology and Prevention of Renal Cell Carcinoma. Cancers (Basel). 2022; 14(16): 4059. DOI:10.3390/cancers14164059; Samnani S., Sachedina F., Gupta M., et al. Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors. Cancer Drug Resist 2023;6:416-29. http://dx.doi.org/10.20517/cdr.2023.02; Lecis D., Sangaletti S., Colombo M.P., Chiodoni C. Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. Cancers (Basel). 2019;11(5):624. doi:10.3390/cancers11050624.; Xu W., Atkins M.B., McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020; 17: 137–150. https://doi.org/10.1038/s41585-020-0282-3.; Lasorsa F., di Meo N.A., Rutigliano M., et al. Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. Biomedicines. 2023; 11: 1071. https://doi.org/10.3390/biomedicines11041071; López de Andrés J., Griñán-Lisón C., Jiménez G., Marchal J.A. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J Hematol Oncol. 2020;13(1):136. doi:10.1186/s13045-020-00966-3.; Munn D.H., Mellor A.L. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37(3):193–207.; Moar P., Tandon R. Galectin-9 as a biomarker of disease severity. Cell Immunol. 2021;361:104287. doi:10.1016/j.cellimm.2021.104287.; Cai J., Wang D., Zhang G., Guo X. The role of PD-1/PD-L1 axis in treg development and function: implications for cancer immunotherapy. Onco Targets Ther. 2019; 12: 8437-8445; Seeber A., Klinglmair G., Fritz J., et al. High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma. Cancer Sci. 2018;109(5):15831591. doi:10.1111/cas.13560.; Maier M.K., et al. The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens. Eur. J. Immunol. 2007; 37(8): 2214–2225.; Liu S., Liang J., Liu Z., et al. The Role of CD276 in Cancers. Front Oncol. 2021;11:654684. doi:10.3389/fonc.2021.654684.; Liao G., Wang P., Wang Y. Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment. Front Oncol. 2021;11:720125. doi:10.3389/fonc.2021.720125.; Hoda R.S., Brogi E., Dos Anjos C.H., et al. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Mod Pathol. 2020;33(11):2221-2232. doi:10.1038/s41379-020-0606-0.; https://www.medgen-journal.ru/jour/article/view/2369

الاتاحة: https://www.medgen-journal.ru/jour/article/view/2369
https://doi.org/10.25557/2073-7998.2023.11.13-19

المؤلفون: D. Zh. Mansorunov, F. M. Kipkeeva, T. A. Muzaffarova, M. P. Nikulin M.P., O. A. Malikhova, N. V. Apanovich, A. A. Alimov, Д. Ж. Мансорунов, Ф. М. Кипкеева, Т. А. Музаффарова, М. П. Никулин, О. А. Малихова, Н. В. Апанович, А. А. Алимов

المساهمون: The research was carried out within the state assignment and funding of the Ministry of Science and Higher Education of the Russian Federation., Работа выполнена в рамках государственного задания Минобрнауки России для ФГБНУ «Медико-генетический научный центр имени академика Н.П. Бочкова».

المصدر: Medical Genetics; Том 22, № 6 (2023); 24-31 ; Медицинская генетика; Том 22, № 6 (2023); 24-31 ; 2073-7998

مصطلحات موضوعية: микросателлитная нестабильность, expression, gastric cancer, immune checkpoint, epithelial-mesenchymal transition, microsatellite instability, экспрессия, рак желудка, иммунные контрольные точки, эпителиально-мезенхимальный переход

وصف الملف: application/pdf

Relation: https://www.medgen-journal.ru/jour/article/view/2318/1719; Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May 4;71(3):209–249.; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022.; Бесова Н.С., Болотина Л.В., Гамаюнов С.В. и др. Практические рекомендации по лекарственному лечению рака желудка. Злокачественные опухоли. 2022 Dec 24;12(3s2-1):382–400.; The Cancer Genome Atlas Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014 Sep 11;513(7517):202-209.; Cristescu R, Lee J, Nebozhyn M et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015 May 20;21(5):449–456.; Prescribing information for KEYTRUDA® (pembrolizumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s128lbl.pdf; Ratti M., Lampis A., Hahne J.C. et al. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018 Nov 1;75(22):4151– 4162.; Kang F.B., Wang L., Jia H.C. et al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-tomesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015 Apr 21;15(45).; Wang Y., Wang H., Zhao Q. et al. PD-L1 induces epithelial-tomesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med Oncol. 2015 Aug;32(8):212.; Ock C.Y., Kim S., Keam B. et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget. 2016 Mar 29;7(13):15901–15914.; Xu D., Li J., Li R. et al. PD-L1 Expression Is Regulated By NF-κB During EMT Signaling In Gastric Carcinoma. Onco Targets Ther. 2019 Nov 25;12:10099–10105.; Goel A., Nagasaka T., Hamelin R., Boland C.R. An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers. Najbauer J, editor. PLoS One. 2010 Feb 24;5(2):e9393.; Luchini C., Bibeau F., Ligtenberg M.J.L. et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019 Aug 1;30(8):1232–1243.; Pham Q.T., Taniyama D., Akabane S. et al. Essential Roles of TDO2 in Gastric Cancer: TDO2 Is Associated with Cancer Progression, Patient Survival, PD-L1 Expression, and Cancer Stem Cells. Pathobiology. 2023;90(1):44-55.; Xiao Y., Yang K., Wang Z. et al. CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression. Front Surg. 2022 Feb 3;8:775194.; Xu M., Zhou H., Zhang C. et al. ADAM17 promotes epithelialmesenchymal transition via TGF-α/Smad pathway in gastric carcinoma cells. Int J Oncol. 2016 Dec;49(6):2520–2528.; Yang B., Wang C., Xie H. et al. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis. 2019 Oct 14;10(10):784.; Zheng Q., Gao J., Yin P. et al. CD155 contributes to the mesenchymal phenotype of triple-negative breast cancer. Cancer Sci. 2020 Feb;111(2):383-394.; https://www.medgen-journal.ru/jour/article/view/2318

الاتاحة: https://www.medgen-journal.ru/jour/article/view/2318
https://doi.org/10.25557/2073-7998.2023.06.24-31

المؤلفون: O. S. Boeva, V. A. Kozlov, A. E. Sizikov, M. A. Korolev, O. A. Chumasova, V. O. Omelchenko, Yu. D. Kurochkina, E. A. Pashkina, О. С. Боева, В. А. Козлов, А. Э. Сизиков, М. А. Королев, О. А. Чумасова, В. О. Омельченко, Ю. Д. Курочкина, Е. А. Пашкина

المساهمون: The study was carried out within the framework of research project No. 122012000366-9 “Study of the immunopathogenesis of phenotypes of socially significant human diseases and polymorbidity as a basis for the development of new methods of personalized diagnosis and treatment”., Исследование выполнено в рамках темы НИР № 122012000366-9 «Изучение иммунопатогенеза фенотипов социально значимых заболеваний человека и полиморбидности как основа для разработки новых методов персонифицированной диагностики и лечения».

المصدر: Medical Immunology (Russia); Том 25, № 5 (2023); 1085-1090 ; Медицинская иммунология; Том 25, № 5 (2023); 1085-1090 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: цитокины, rheumatoid arthritis, immune checkpoint molecules, flow cytometry, cytokines, ревматоидный артрит, контрольные точки иммунного ответа, проточная цитометрия

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2786/1767; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2786/11646; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2786/11662; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2786/11664; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2786/11665; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2786/11667; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2786/11668; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2786/11673; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2786/12235; Bal S.M., Golebski K., Spits H. Plasticity of innate lymphoid cell subsets. Nat. Rev. Immunol., 2020, Vol. 20, no. 9, pp. 552-565.; Clottu A.S., Humbel M., Fluder N., Karampetsou M.P., Comte D. Innate lymphoid cells in autoimmune diseases. Front. Immunol., 2022, Vol. 12, 789788. doi:10.3389/fimmu.2021.789788.; Edilova M.I., Akram A., Abdul-Sater A.A. Innate immunity drives pathogenesis of rheumatoid arthritis. Biomed. J., 2021, Vol. 44, no. 2, pp. 172-182.; Herman S., Zurgil N., Langevitz P., Ehrenfeld M., Deutsch M. Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients. Clin. Exp. Rheumatol., 2008, Vol. 26, no. 2, pp. 317-323.; Kato M., Ikeda K., Sugiyama T., Tanaka S., Iida K., Suga K., Nishimura N., Mimura N., Kasuya T., Kumagai T., Furuya H., Iwamoto T., Iwata A., Furuta S., Suto A., Suzuki K., Kawakami E., Nakajima H. Associations of ultrasound-based inflammation patterns with peripheral innate lymphoid cell populations, serum cytokines/ chemokines, and treatment response to methotrexate in rheumatoid arthritis and spondyloarthritis. PLoS One, 2021, Vol. 16, no. 5, e0252116. doi:10.1371/journal.pone.0252116.; McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med., 2011, Vol. 365, no. 23, pp. 2205-2219.; Mjosberg J., Spits H. Human innate lymphoid cells. J. Allergy Clin. Immunol., 2016, Vol. 138, no. 5, pp. 1265-1276.; Marsal S., Julia A. Rheumatoid arthritis pharmacogenomics. Pharmacogenomics, 2010, Vol. 11, no. 5, pp. 617-619.; Smolen J.S., Aletaha D., Bijlsma J.W., Breedveld F.C., Boumpas D., Burmester G.,Combe B., Cutolo M., de Wit M., Dougados M., Emery P., Gibofsky A., Gomez-Reino J.J., Haraoui B., Kalden J., Keystone E.C., Kvien T.K., McInnes I., Martin-Mola E., Montecucco C., Schoels M., van der Heijde D.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis., 2010, Vol. 69, no. 4, pp. 631-637.; Tamimoto Y., Horiuchi T., Tsukamoto H., Otsuka J., Mitoma H., Kimoto Y., Nakashima H., Muta K., Abe Y., Kiyohara C., Ueda A., Nagasawa K., Yoshizawa S., Shimoda T., Harada M. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford), 2008, Vol. 47, no. 6, pp. 821-827.; Taylor S., Huang Y., Mallett G., Stathopoulou C., Felizardo T.C., Sun M.A., Martin E.L., Zhu N., Woodward E.L., Elias M.S., Scott J., Reynolds N.J., Paul W.E., Fowler D.H., Amarnath S. PD-1 regulates KLRG1+ group 2 innate lymphoid cells. J. Exp. Med., 2017, Vol. 214, no. 6, pp. 1663-1678.; Wang T., Rui J., Shan W., Xue F., Feng D., Dong L., Mao J., Shu Y., Mao C., Wang X. Imbalance of Th17, Treg, and helper innate lymphoid cell in the peripheral blood of patients with rheumatoid arthritis. Clin. Rheumatol., 2022, Vol. 41, pp. 3837-3849.; Wu X. Innate Lymphocytes in Inflammatory Arthritis. Front. Immunol., 2020, Vol. 11, 565275. doi:10.3389/fimmu.2020.565275.; https://www.mimmun.ru/mimmun/article/view/2786

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2786
https://doi.org/10.15789/1563-0625-COP-2786

المؤلفون: A. A. Aktanova, M. V. Bykova, O. S. Boeva, E. A. Pashkina, L. V. Grishina, V. A. Kozlov, А. А. Актанова, М. В. Быкова, О. С. Боева, Е. А. Пашкина, Л. В. Гришина, В. А. Козлов

المساهمون: This study was supported by Russian Science Foundation according to the research project No. 19-15-00192.

المصدر: Medical Immunology (Russia); Том 25, № 3 (2023); 697-702 ; Медицинская иммунология; Том 25, № 3 (2023); 697-702 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: проточная цитометрия, macrocyclic complexes, carboplatin, oxaliplatin, Tregs, immune checkpoint molecules, flow cytometry, макроциклические комплексы, карбоплатин, оксалиплатин, T-регуляторные клетки, контрольные точки иммунного ответа

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2752/1730; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11399; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11400; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11401; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11402; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11403; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11404; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11405; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11406; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11407; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11635; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2752/11868; Aksoylar H.I., Boussiotis V.A. PD-1+ Treg cells: a foe in cancer immunotherapy? Nat. Immunol., 2020, Vol. 21, pp. 1311-1312.; Csapo M., Lazar L. Chemotherapy-induced cardiotoxicity: Pathophysiology and prevention. Clujul Med., 2014, Vol. 87, no. 3, pp. 135-142.; Galli F., Aguilera J.V., Palermo B., Markovic S.N., Paola Nisticò P., Signore A. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J. Exp. Clin. Cancer Res., 2020, Vol. 39, 89. doi:10.1186/s13046-020-01586-y.; Kim N.R., Kim Y.J. Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-κB signaling. Cancer Med., 2019, Vol. 8, no. 1, pp. 276-288.; Kovalenko E.A., Pashkina E.A., Kanazhevskaya L.Y., Masliy A.N., Kozlov V.A. Chemical and biological properties of a supramolecular complex of tuftsin and cucurbit[7]uril. Int. Immunopharmacol., 2017, Vol. 47, pp. 199-205.; Lees J.G., White D., Keating B.A., Barkl-Luke M.E., Makker P.G.S., Goldstein D., Moalem-Taylor G. Oxaliplatin-induced haematological toxicity and splenomegaly in mice. PLoS One, 2020, Vol. 15. no. 9, e0238164. doi:10.1371/journal.pone.0238164.; Montes-Navajas P., González-Béjar M., Scaiano J.C., García H. Cucurbituril complexes cross the cell membrane.Photochem. Photobiol. Sci., 2009, Vol. 8, no. 12, pp. 1743-1747.; Piersiala K., da Silva P.F.N., Lagebro V., Kolev A., Starkhammar M., Elliot A., Marklund L., Munck-Wikland E., Margolin G., Georén S.K., Cardell L.O. Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. Transl. Oncol., 2022, Vol. 23, 101469. doi:10.1016/j.tranon.2022.101469.; Principe D.R., Chiec L., Mohindra N.A., Munshi H.G. Regulatory T-cells as an emerging barrier to immune checkpoint inhibition in lung cancer. Front. Oncol., 2021, Vol. 11, 684098. doi:10.3389/fonc.2021.684098.; Sobhani N., Tardiel-Cyril D.R., Davtyan A., Generali D., Roudi R., Li Y. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. Cancers (Basel), 2021, Vol. 13, no. 6, 1440. doi:10.3390/cancers13061440.; Suzuki S., Ogawa T., Sano R., Takahara T., Inukai D., Akira S., Tsuchida H., Yoshikawa K., Ueda R., Tsuzuki T. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. Cancer Sci., 2020, Vol.111, no. 6, pp. 1943-1957.; Vankerckhoven A., Baert T., Riva M., de Bruyn C., Thirion G., Vandenbrande K., Ceusters J., Vergote I., Coosemans A. Type of chemotherapy has substantial effects on the immune system in ovarian cancer. Transl. Oncol., 2021, Vol. 14, no. 6, 101076. doi:10.1016/j.tranon.2021.101076.; Zhou J., Kang Y., Chen L., Wang H., Liu J., Zeng S., Yu L. The drug-resistance mechanisms of five platinumbased antitumor agents. Front. Pharmacol., 2020, Vol. 11 343. doi:10.3389/fphar.2020.00343.; https://www.mimmun.ru/mimmun/article/view/2752

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2752
https://doi.org/10.15789/1563-0625-CBS-2752

المؤلفون: Плотников, Евгений Владимирович, Оружени, М., Безверхняя, Екатерина Александровна, Сю, Т., Лю, Ю., Карлберг, И., Орлова, Анна Марковна, Толмачев, Владимир Максимилианович, Фрейд, Ф. Ю.

مصطلحات موضوعية: таргетная терапия, визуализация, иммунная система, контрольные точки, таргетные свойства, опухоли, иммунный ответ

وصف الملف: application/pdf

Relation: Физико-технические проблемы в науке, промышленности и медицине : сборник тезисов докладов XI Международной научно-практической конференции, г. Томск, 07–09 сентября 2022 г.; Изучение in vitro таргетного агента на основе аффибоди для визуализации молекулы иммунной контрольной точки / Е. В. Плотников, М. Оружени, Е. А. Безверхняя [и др.] // Физико-технические проблемы в науке, промышленности и медицине : сборник тезисов докладов XI Международной научно-практической конференции, г. Томск, 07–09 сентября 2022 г. — Томск : Изд-во ТПУ, 2022. — [С. 107-108].; http://earchive.tpu.ru/handle/11683/74573

الاتاحة: http://earchive.tpu.ru/handle/11683/74573

المصدر: Алматы технологиялық университетінің хабаршысы, Vol 0, Iss 2 (2022)

مصطلحات موضوعية: потенциальные опасности, критические контрольные точки, мясо птицы, уф -излучение, предубойная выдержка, хранение готовой продукции, безопасность облученного мяса, Technology (General), T1-995

وصف الملف: electronic resource

Relation: https://www.vestnik-atu.kz/jour/article/view/534; https://doaj.org/toc/2304-568X; https://doaj.org/toc/2710-0839

URL الوصول: https://doaj.org/article/c8d2902a53874f5a94b95baa1ee6659a

المصدر: Алматы технологиялық университетінің хабаршысы, Vol 0, Iss 1, Pp 16-21 (2021)

مصطلحات موضوعية: молочная промышленность, haccp, контрольные точки, риски, качество, безопасность, Technology (General), T1-995

وصف الملف: electronic resource

Relation: https://www.vestnik-atu.kz/jour/article/view/31; https://doaj.org/toc/2304-568X; https://doaj.org/toc/2710-0839

URL الوصول: https://doaj.org/article/f2bb11a618594925954c0c37df5dec63

المصدر: Алматы технологиялық университетінің хабаршысы, Vol 0, Iss 2 (2022)

مصطلحات موضوعية: потенциальные опасности, критические контрольные точки, мясо птицы, уф -излучение, предубойная выдержка, хранение готовой продукции, безопасность облученного мяса, Technology (General), T1-995

Relation: https://www.vestnik-atu.kz/jour/article/view/534; https://doaj.org/toc/2304-568X; https://doaj.org/toc/2710-0839; https://doaj.org/article/c8d2902a53874f5a94b95baa1ee6659a

الاتاحة: https://doaj.org/article/c8d2902a53874f5a94b95baa1ee6659a

المؤلفون: Гилязова, И. Р., Асадуллина, Д. Д., Иванова, Е. А., Рахимов, Р. Р., Измайлов, А. А.

مصطلحات موضوعية: медицина, медицинская генетика, ингибиторы, контрольные точки иммунитета, PD-1, лекарственная резистентность, почечно-клеточная карцинома, генетика, герминальные мутации

Relation: Герминальные мутации как возможные биомаркеры эффективности терапии ингибиторами контрольных точек иммунитета у пациентов с почечно-клеточной карциномой : мини-обзор / И.Р. Гилязова [и др.] // Научные результаты биомедицинских исследований. - 2022. - Т.8, №2.-С. 164-179. - Doi:10.18413/2658-6533-2022-8-2-0-3. - Библиогр.: с. 172-177.; http://dspace.bsu.edu.ru/handle/123456789/48329

الاتاحة: http://dspace.bsu.edu.ru/handle/123456789/48329

المؤلفون: М.В. Белогай, Л.В. Латыпова

المصدر: ИННОВАЦИОННЫЕ НАУЧНЫЕ ИССЛЕДОВАНИЯ, 2021 № 2-2(4), 32-42, (2021-02-27)

مصطلحات موضوعية: СМБПП, ГОСТ Р ИСО 22000-2019, ХАССП, пищевая промышленность, критические контрольные точки, анализ опасностей, опрос, аудит

Relation: https://doi.org/10.5281/zenodo.4568000; https://doi.org/10.5281/zenodo.4568001; oai:zenodo.org:4568001

الاتاحة: https://doi.org/10.5281/zenodo.4568001

المؤلفون: Tungyshbayeva, U. (Ulbala), Mannino, S. (Saverio), Uazhanova, R. (Raushangul), Adilbekov, M. A. (Mamyrbek), Yakiyayeva, M. A. (Madina), Kazhymurat, A. (Assemay)

المصدر: Eastern-European Journal of Enterprise Technologies

مصطلحات موضوعية: ХАССП, критичні контрольні точки, хлібобулочні вироби, безпека та якість харчових продуктів, критические контрольные точки, хлебобулочные изделия, безопасность и качество пищевых продуктов, HACCP, critical control points, bakery products, food safety and quality, Indonesia

وصف الملف: application/pdf

Relation: https://www.neliti.com/publications/400733/development-of-a-methodology-for-determining-the-critical-limits-of-the-critical

الاتاحة: https://www.neliti.com/publications/400733/development-of-a-methodology-for-determining-the-critical-limits-of-the-critical

المؤلفون: E. Fedchenko A., A. Buryakova O., Е. Федченко А., А. Бурякова О.

المصدر: Vestnik Universiteta; № 12 (2020); 76-86 ; Вестник университета; № 12 (2020); 76-86 ; 2686-8415 ; 1816-4277

مصطلحات موضوعية: budget execution, control points, efficiency, government programs, mathematical modeling, methodology, quality of planning, system of criteria, государственные программы, исполнение бюджета, качество планирования, контрольные точки, математическое моделирование, методика, система критериев, эффективность

وصف الملف: application/pdf

Relation: https://vestnik.guu.ru/jour/article/view/2574/1933; Бюджетный кодекс Российской Федерации № 145-ФЗ от 31.07.1998 с изменениями (ред. от 15.10.2020) // СПС «КонсультантПлюс» [Электронный ресурс]. – Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_19702/ (дата обращения: 29.10.2020).; Федеральный закон «О стратегическом планировании в Российской Федерации» № 172-ФЗ от 29.11.2014 с изменениями 2020 г. (ред. от 31.07.2020) // СПС «КонсультантПлюс» [Электронный ресурс]. – Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_164841/ (дата обращения: 28.10.2020).; Федеральный закон «О федеральном бюджете на 2018 год и на плановый период 2019 и 2020 годов» № 362-ФЗ от 05.12.2017 // СПС «КонсультантПлюс» [Электронный ресурс]. – Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_284360/ (дата обращения: 27.10.2020).; Постановление Правительства Российской Федерации «Об утверждении Правил формирования сводного годового доклада о ходе реализации и оценке эффективности государственных программ Российской Федерации, внесении изменений в некоторые акты Правительства Российской Федерации и признании утратившими силу отдельных положений некоторых актов Правительства Российской Федерации» № 903 от 17.07.2019 с изменениями 2020 г. (ред. от 30.05.2020) // СПС «КонсультантПлюс» [Электронный ресурс]. – Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_329312/ (дата обращения: 27.10.2020).; Приказ Минэкономразвития России «Об утверждении Методических указаний по разработке и реализации государственных программ Российской Федерации» № 582 от 16.09.2016 с изменениями 2017 г. (ред. от 15.03.2017) // СПС «КонсультантПлюс» [Электронный ресурс]. – Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_205801/ (дата обращения: 27.10.2020).; Приказ Минэкономразвития России «Об утверждении Методики оценки эффективности реализации государственной программы Российской Федерации «Экономическое развитие и инновационная экономика» № 351 от 17.07.2017) // СПС «КонсультантПлюс» [Электронный ресурс]. – Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_221073/03f265c3af2e7302b72fbc4758da6d0953ae15e5/ (дата обращения: 27.10.2020).; Материалы Министерства экономического развития Российской Федерации о распределении государственных программ Российской Федерации по результатам оценки эффективности их реализации в 2018 г. [Электронный ресурс]. – Режим доступа: http://static.government.ru/media/files/tWquoiCll0TkyTXMSvrK8VTCJtecEcgn.pdf (дата обращения: 27.10.2020).; Аркадьева, О. Г. Оценка эффективности реализации государственных программ: методические аспекты формирования отчетности // Экономический анализ: теория и практика. – 2018. – № 1. – С. 184-200.; Варнавский, А. В., Волкова, Е. С., Бурякова, А. О., Климова, Е. А. Модель оценки цифрового лидерства организации // Вестник университета. – 2020. – № 4. – С. 23-32.; Саати, Т. Принятие решений. Метод анализа иерархий. – М.: Радио и связь, 1993. – 278 с.; Тихомирова, А. Н., Сидоренко, Е. В. Модификация метода анализа иерархий Т. Саати для расчета весов критериев при оценке инновационных проектов // Современные проблемы науки и образования. – 2012. – № 2. – С. 261-261.; Фомина, Е. А., Ходковская, Ю. В. Программный бюджет: развитие методологии // Финансы Башкортостана. – 2016. – № 4. – С. 63-65.; Черникин, О. С., Прохорова, А. В. Субсидия на выполнение государственного задания как элемент программного бюджета // Вестник Тверского государственного университета. – 2016. – № 4. – С. 77-81.; https://vestnik.guu.ru/jour/article/view/2574

الاتاحة: https://vestnik.guu.ru/jour/article/view/2574
https://doi.org/10.26425/1816-4277-2020-12-76-86

المؤلفون: R. Kurbanov K., N. Zakharova I., D. Gorshkov M., Р. Курбанов К., Н. Захарова И., Д. Горшков М.

المصدر: Agricultural Machinery and Technologies; Том 15, № 4 (2021); 42-47 ; Сельскохозяйственные машины и технологии; Том 15, № 4 (2021); 42-47 ; 2618-6748 ; 2073-7599

مصطلحات موضوعية: digital farming, remote sensing, unmanned aerial vehicle, ground control points, high-precision aerial photography, цифровое земледелие, дистанционное зондирование, беспилотное воздушное судно, наземные контрольные точки, опорные точки, высокоточная аэрофотосъемка

وصف الملف: application/pdf

Relation: https://www.vimsmit.com/jour/article/view/449/403; Mogili U.R., Deepak B.B.V.L. Review on application of drone systems in precision agriculture. Procedia Computer Science. 2018. N133. 502-509.; Измайлов А.Ю., Лобачевский Я.П., Дорохов А.С., Сиби­рев А.В., Крючков В.А., Сазонов Н.В. Современные технологии и техника для сельского хозяйства – тенденции выставки Agritechnika 2019 // Тракторы и сельхозмашины. 2017. N6. С. 28-40.; Maes W.H., Steppe K. Perspectives for remote sensing with unmanned aerial vehicles in precision agriculture. Trends in Plant Science. 2019. N24(2). 152-164 .; Лачуга Ю.Ф., Измайлов А.Ю., Лобачевский Я.П., Шоге­нов Ю.Х. Развитие интенсивных машинных технологий, роботизированной техники, эффективного энергообеспечения и цифровых систем в агропромышленном комплексе // Техника и оборудование для села. 2019. N6 (264). С. 2-9.; Личман Г.И., Коротченя В.М., Смирнов И.Г., Курба­нов Р.К. Концепция точного земледелия на основе понятий идеального поля и цифрового двойника // Электротехнологии и электрооборудование в АПК. 2020. N67(3). С. 81-86.; Курбанов Р.К., Костомахин М.Н., Захарова Н.И., Захарова О.М., Бабков С.В. Рекомендации для легких беспилотных летательных аппаратов по сбору данных // Сельскохозяйственная техника: обслуживание и ремонт. 2018. N6. С. 47-53.; Артюшин А.А., Курбанов Р.К., Марченко Л.А., Захарова О.М. Выбор типоразмерного ряда беспилотных летательных аппаратов и полезной нагрузки для мониторинга сельскохозяйственных полей // Электротехнологии и электрооборудование в АПК. 2019. N4 (37). С. 36-43.; Matese A., Di Gennaro S.F. Beyond the traditional NDVI index as a key factor to mainstream the use of UAV in precision viticulture. Scientific Reports. 2021. N11. 2721.; Курбанов Р.К., Захарова Н.И., Гайдук О.М. Использование теплового канала (LWIR) для оценки состояния посевов и прогнозирования урожайности сельскохозяйственных культур // Электротехнологии и электрооборудование в АПК. 2020. N67(3). С. 87-94.; Tamouridou A.A., Alexandridis T.K., Pantazi X.E., Lagopodi A.L., Kashefi J., Kasampalis D., Kontouris G., Moshou D. Application of Multilayer Perceptron with Automatic Relevance Determination on Weed Mapping Using UAV Multispectral Imagery. Sensors. 2017. N17. 2307.; Han X., Thomasson J.A., Xiang Y., Gharakhani H., Yadav P.K., Rooney W.L. Multifunctional Ground Control Points with a Wireless Network for Communication with a UAV. Sensors. 2019. N19(13). 2852.; Pessoa G.G., Carrilho A.C., Miyoshi G.T. Assessment of UAV-based digital surface model and the effects of quantity and distribution of ground control points. International Journal of Remote Sensing. 2021. Vol. 42. 65-83.; Liu J., Xu W., Guo B., Zhou G., Zhu H. Accurate Mapping Method for UAV Photogrammetry Without Ground Control Points in the Map Projection Frame. IEEE Transactions on Geoscience and Remote Sensing. 2021. 1-9.; Курбанов Р.К., Захарова О.М. Рекомендации по предполетной подготовке БПЛА // Электротехнологии и электрооборудование в АПК. 2020. Т. 67. N1(38). С. 93-98.; Daugela I., Visockiene J.S., Kumpiene J. Detection and analysis of methane emissions from a landfill using unmanned aerial drone systems and semiconductor sensors. Detritus. 2020. Vol. 10. 127-138.; Beranek C.T., Roff A., Denholm B., Howell L.G., Witt R.R. Trialling a real-time drone detection and validation protocol for the koala (Phascolarctos cinereus). Australian Mammalogy. 2020. N43(2). 260-264.; Kapicioglu H.S., Hastaoglu K.O., Poyraz F., Gül Y. Investigation of topographic effect in ground control point selection in UAV photogrammetry: Gaziantep/ Nizip. International conference on innovative engineering applications. 2018. 1174-1178.; Martínez-Carricondo P., Agüera-Vega F., Carvajal-Ramírez F. Assessment of UAV-photogrammetric mapping accuracy based on variation of ground control points. International Journal of Applied Earth Observation and Geoinformation. 2018. Vol. 72. 1-10.; Ferrer-González E., Agüera-Vega F., Carvajal-Ramírez F., Martínez-Carricondo P. UAV Photogrammetry Accuracy Assessment for Corridor Mapping Based on the Number and Distribution of Ground Control Points. Remote Sensing. 2020. N12.; Gómez-Candón D., De Castro A.I., López-Granados F. Assessing the accuracy of mosaics from unmanned aerial vehicle (UAV) imagery for precision agriculture purposes in wheat. Precision Agriculture. 2014. N15(1). 44-56.; Kim J. S., Hong Y. Accuracy Analysis of Photogrammetry Based on the Layout of Ground Control Points Using UAV. Journal of the Korean Cartographic Association. 2020. N20(2). 41-55.; Santana L.S., Ferraz G.A.E.S., Marin D.B., Barbosa B.D.S., et al. Influence of flight altitude and control points in the georeferencing of images obtained by unmanned aerial vehicle. European Journal of Remote Sensing. 2021. Vol. 54. Iss. 1. 59-71.; https://www.vimsmit.com/jour/article/view/449

الاتاحة: https://www.vimsmit.com/jour/article/view/449
https://doi.org/10.22314/2073-7599-2021-15-4-42-47

المؤلفون: A. V. Chetveryakov, V. L. Tsepelev, А. В. Четверяков, В. Л. Цепелев

المصدر: Acta Biomedica Scientifica; Том 6, № 4 (2021); 146-159 ; 2587-9596 ; 2541-9420

مصطلحات موضوعية: иммунные контрольные точки, tumor immunotherapy, PD-1, immune control points, иммунотерапия опухолей

وصف الملف: application/pdf

Relation: https://www.actabiomedica.ru/jour/article/view/2982/2199; Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999; 11(2): 141-151. doi:10.1016/s1074-7613(00)80089-8; Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T-cell tolerance. J Exp Med. 2006; 203(4): 883-895. doi:10.1084/jem.20051776; Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, et al. PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. Cancer Treat Rev. 2015; 41(2): 114-121. doi:10.1016/j.ctrv.2014.12.01; Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012; 24(2): 207-212. doi:10.1016/j.coi.2011.12.009; Rosenwald A, Wright G, Leroy K, Xin Yu, Gaulard Ph, et al. Molecular diagnosis of primary mediastinal B-cell lymphoma identifies a clinically favorable subgroup of diffuse large B-cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003; 198(6): 851-862. doi:10.1084/jem.20031074; Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5(12): 1365-1369. doi:10.1038/70932; Galluzzi L, Buque A, Keep O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015; 28(6): 690-714. doi:10.1016/j.ccell.2015.10.012; Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD–L2 is a second ligand for PD-1 and inhibits T-cell activation. Nat Immunol. 2001; 2(3): 261-268. doi:10.1038/85330; Zhao C, Telia SH, Del Rivero J, Kommalapati A, Ebenuwa I, Gulley J, et al. Anti-PD-L1 treatment induced central diabetes insipidus. J Clin Endocrinol Metab. 2018; 103(2): 365-369. doi:10.1210/jc.2017-01905; Spencer CW, Colm RD, James PA. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018; 8(9): 1069-1086. doi:10.1158/2159-8290; Peng Q, Deng Z, Pan H, Gu L, Liu O, Tang Z. Mitogenactivated protein kinase signaling pathway in oral cancer. Oncol Lett. 2018; 15(2): 1379-1388. doi:10.3892/ol.2017.7491; Stutvoet TS, Kol A, de Vries EG, de Bruyn M, Fehrmann RS, Terwisscha van Scheltinga AG, et al. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. J Pathol. 2019; 249(1): 52-64. doi:10.1002/path.5280; Jalali S, Price-Troska T, Bothun C, Villasboas J, Kim HJ, Yang ZZ, et al. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer J. 2019; 9(3): 22. doi:10.1038/s41408-019-0185-9; Groner B, von Manstein V. Jak-Stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017; 451: 1-14. doi:10.1016/j.mce.2017.05.033; Li P, Huang T, Zou Q, Liu D, Wang Y, Tan X, et al. FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK/ STAT3 signaling pathway. J Immunol. 2019; 202(10): 3065-3075. doi:10.4049/jimmunol.1801199; Ribas A. Adaptive immune resistance: How cancer protects from immune attack. Cancer Discov. 2015; 5(9): 915-919. doi:10.1158/2159-8290; Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: Past, present, and future. J Clin Invest. 2015; 125(9): 3384-3391. doi:10.1172/JCI80011; Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phase’s elimination, equilibrium and escape. Curr Opin Immunol. 2014; 27: 16-25. doi:10.1016/j.coi.2014.01.004; Swaika A, Hammond WA, Joseph RW. Current state of antiPD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 2015; 67(2 Pt 2): 4-17. doi:10.1016/j.molimm.2015.02.009; Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007; 13(1): 84-88. doi:10.1038/nm1517; Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014; 2(9): 846-856. doi:10.1158/2326-6066.CIR-14-0040; Trinh B, Sanchez GO, Herzig P, Läubli H. Inflammationinduced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. J Immunother Cancer. 2019; 7(1): 52. doi:10.1186/s40425-019-0528-x; Larkin J, Minor D, D’Angelo S, Neyns B, Smylie M, Miller WH Jr, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in Check Mate 037: A randomized, controlled, open-label phase III trial. J Clin Oncol. 2018; 36(4): 383-390. doi:10.1200/JCO.2016.71.8023; Albarel F, Gaudy C, Castinetti F, Carré T, Morange I, ConteDevolx B, et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015; 172(2): 195-204. doi:10.1530/EJE-14-0845; Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011; 22(4): 991-993. doi:10.1093/annonc/mdr028; Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2): 122-133. doi:10.1056/NEJMoa1302369; Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373(2): 123-135. doi:10.1056/NEJMoa1504627; Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015; 373(17): 1627-1639. doi:10.1056/NEJMoa1507643; Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol. 2015; 33(13): 1430-1437. doi:10.1200/Jœ.2014.59.0703; Adapted from poster presented by Plimack ER, et al. 15th International Kidney Cancer Symposium. Miami, FL, USA; 2016.; Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYN0TE-001. J Clin Oncol. 2016; 34(Suppl 15): 9503-9503. doi:10.1200/JCO.2016.34.15_suppl.9503; Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016; 315(15): 1600-1609. doi:10.1001/jama.2016.4059; Patnaik AM, Socibski MA, Gubens MA, Gandhi L, Stevenson J, Bachman RD, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYN0TE-021 cohort D. J Clin Oncol. 2015; 33(15): 8011. doi:10.1200/jco.2015.33.15_suppl.8011; Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, et al. Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Ann Oncol. 2015; 16(8): 908-918. doi:10.1016/S1470-2045(15)00083-2; Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, et al. Safety and efficacy of nivolumab in patients with advanced non-small-cell lung cancer treated beyond progression. Clin Lung Cancer. 2019; 20(3): 178-185. doi:10.1016/j.cllc.2019.02.001; Лядова М.А., Пардабекова O.A., Шакиров O.A., Лядов В.К., Федянин М.Ю. Ниволумаб в реальной клинической практике. Исследования и практика в медицине. 2019; 6(4): 84-91. doi:10.17709/2409-2231-2019-6-4-8; Саржевский В.О., Демина Е.А., Мочкин Н.Е., Спорник А.А., Мамедова А.А., Смирнова Е.Н.? и др. Ингибиторы контрольных точек и классическая лимфома Ходжкина: эффективность и безопасность пембролизумаба при рецидивах и рефрактерном течении опухоли (опыт ФГБУ «НМХЦ им. Н.И. Пирогова» Минздрава России). Клиническая онкогематология. 2021; 14(1): 53-62. doi:10.21320/2500-2139-2021-14-1-53-62; Ansell S, Lesokhin A, Borrello I, Halwani A, Scott EC, Guttierez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015; 372(4): 311-319. doi:10.1056/NEJMoa1411087; Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205. Trial J Clin Oncol. 2018; 36(14): 1428-1439. doi:10.1200/JC0.2017.76.0793; Armand P, Shipp MA, Ribrag V, Michot J-M, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016; 34(31): 3733-3739. doi:10.1200/JC0.2016.67.3467; Chen R, Zinzani P, Fanale M, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017; 35(19): 2125-2132. doi:10.1200/JC0.2016.72.1316; Zinzani P, Lee H, Armand P, Johnson N, Brice P, Radford J, et al. Three-year follow-up of Keynote-087: Pembrolizumab monotherapy in relapsed/refractory classic Hodgkin lymphoma. Blood. 2019; 134(1): 240. doi:10.1182/blood-2019-127280; Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016; 128(21): 2489-2496. doi:10.1182/blood-2016-05-718528; Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International working group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017; 28(7): 1436-1447. doi:10.1093/annonc/mdx097; Лепик К.В. Эффективность и безопасность PD-1 ингибитора (ниволумаба) в лечении резистентной и рецидивирующей лимфомы Ходжкина: автореф. дис. … канд. мед. наук. СПб.; 2019.; BangYJ, Doi T, Braud FD, Piha-Paul S, Hollebecque A, Abdul Razak AR, et al. Safety and efficacy of pembrolizumab in patients with advanced biliary tract cancer: Interim results of KEYNOTE-028. Eur J Cancer. 2015; 51(3): 112. doi:10.1016/S0959-8049(16)30326-4; Abou-Alfa GK, Macarulla Mercade T, Javle M, Kelley RK, Lubney S, Adeva J, et al. ClarlDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann Oncol. 2019; 30(Suppl 5): v851-v934. doi:10.1093/annonc/mdz394; Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, de JesusAcosta A, Delord J-P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite Instability/mismatch repairdeficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020; 38(1): 1-10. doi:10.1200/JCO.19.02105; Jan der Zwan JM, Trama A, Otter R, Larranaga N, Tavilla A, Marcos-Gragera R, et al. Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013; 49(11): 2565-2578. doi:10.1016/j.ejca.2013.02.029; Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016; 374(26): 2542-2552. doi:10.1056/NEJMoa1603702; Topalian SL, Bhatia S, Hollebecque A, Awada A, De Boer JP, Kudchadkar RR, et al. Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). Cancer Res. 2017; 77(13): CT074. doi:10.1158/1538-7445.AM2017-CT074; Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016; 17(10): 1374-1385. doi:10.1016/S1470-2045(16)30364-3; Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018; 6: 7. doi:10.1186/s40425-017-0310-x; Орлова К.В., Назарова В.В., Петенко Н.Н., Демидов Л.В. Авелумаб в лечении пациентов с карциномой Меркеля: первые результаты программы раннего доступа в России. Злокачественные опухоли. 2019; 9(1): 53-58. doi: 10.18 027/2224-5057-2019-9-1-53-58; Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6): 717-726. doi:10.1016/S1470-2045(16)00175-3; Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018; 4(5): e180013. doi:10.1001/jamaoncol2018.0013; Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, et al. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophagealjunction cancer: Phase 1b results from the JAVELIn Solid Tumor trial. J Immunother Cancer. 2019; 7(1): 30. doi:10.1186/s40425-019-0508-1; Ogata D, Tsuchida T. Systemic immunotherapy for advanced cutaneous squamous cell carcinoma. Curr Treat Options Oncol. 2019; 20: 30. doi:10.1007/s11864-019-0629-2; https://www.actabiomedica.ru/jour/article/view/2982

الاتاحة: https://www.actabiomedica.ru/jour/article/view/2982
https://doi.org/10.29413/ABS.2021-6.4.13